Ambea repurchases own shares

Repurchased shares will be saved to be used under Ambea’s share savings plan. The buyback program will be managed by a securities company or credit institution that makes its trading decisions regarding Ambea’s shares independently of, and without influence by, Ambea with regard to the timing of the repurchases. The buyback program shall meet the following terms: 1. Repurchases of shares are to be made on Nasdaq Stockholm and in accordance with Nasdaq Stockholm’s Rule Book for Issuers. 2. Share repurchases can be made in the period from November 20, 2017 to May 22, 2018. 3. Repurchases of shares on Nasdaq Stockholm are to be made at a per-share price within the registered interval for the going rate at any given time, which denotes the interval between the highest and lowest selling price. 4. A maximum of 62,277 shares may be repurchased. The Company’s holding of its own shares may not at any time exceed 1 per cent of the outstanding shares in the Company. 5. Payment for the shares is to be made in cash. The total number of outstanding registered shares in Ambea amounts to 67,616,556. Currently, Ambea does not hold any own shares. For more information, contact: Louise Tjeder, Director IR and StrategyTelephone: +46 731 43 17 68E-mail: The information was submitted for publication, through the agency of the contact person set out above, at 7.00 CET on November 17, 2017. Ambea is present within care services and has around 14,000 employees. Ambea offers services within disabled care, individual and family care and elderly care, with a focus on residential care and own management. We strive to be the quality leaders in all we do – and our vision is to make the world better, one person at a time. As of December 31, 2016, Ambea had approximately 6,200 beds and 1,300 school-/daily activity-placements in around 460 units across Sweden and Norway. Total sales and adjusted EBITA for the 2016 financial year amounted to SEK 5,409 million and SEK 456 million. The company was founded in 1996 and its head office is located in Solna, Sweden. Ambea is listed on Nasdaq Stockholm.

BerGenBio ASA: Results for the Third Quarter 2017

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are very pleased with the progress the company has made during Q3 2017. Our broad clinical development programme of Phase 2 trials with BGB324, our selective Axl inhibitor, in combination with standard therapies in multiple aggressive cancers is well underway and recruiting patients at leading hospitals in Europe and the US. These trials are on track to deliver important clinical milestones in 2H 2018, demonstrating the significant potential of BGB324 to become a universal approach to cancer therapy by making tumour cells visible to the immune system and more susceptible to treatment with chemotherapy, targeted therapy and immuno-oncology drugs.” Operational highlights · Good progress advancing broad clinical development programme with BGB324 in all indications under investigation · Patient recruitment underway for four company sponsored Phase II trials with key read-outs expected in 2H 2018: two trials in non-small cell lung cancer (NSCLC), one in triple negative breast cancer (TNBC), and in acute myeloid leukaemia (AML) / myelodysplastic syndrome (MDS) · Two Phase II investigator-sponsored studies evaluating BGB324 in combination with chemotherapy in NSCLC and with targeted or immune-oncology drugs in melanoma continue to recruit well · Design and rationale for Phase II trial of BGB324 in combination with chemotherapy, targeted therapy and immunotherapy in NSCLC presented at Precision: Lung Cancer Conference, Boston. · Clinical trial programme demonstrating BGB324’s ability to counteract Axl-driven immune evasion and acquired drug resistance to standard therapies with potential to improve clinical outcomes Post period events · First patients enrolled and dosed in Phase II trials of BGB324 in combination with KEYTRUDA® (pembrolizumab) in NSCLC and TNBC (October) · Patient recruitment progressing well at leading cancer centres in Norway, UK, Spain and the US · Clinical and scientific presentations at global cancer conferences (October) · Data from BGB324/docetaxel study showed combination was well-tolerated and one (of three) NSCLC patients had partial remission at ten months and tumour shrinkage – presented at 18th World Conference on Lung Cancer · Strong recruitment and encouraging safety profile of BGB324 in randomised Phase II trial of BGB324 in combination with targeted or immuno-oncology drugs in melanoma patients presented at 9th World Congress of Melanoma Key Figures (NOK Q3 2017 Q3 2016 YTD2017 YTD2016 FY 2016million)Operating revenues  -    -    -    -    -  Operating expenses  36.6  16.3  136.2  103.5  131.6Operating profit (loss)  (36.6)  (16.3)  (136.2)  (103.5)  (131.6)Profit (loss) after tax  (35.4)  (15.4)  (134.6)  (101.9)  (129.8) Basic and diluted  (0.71)  (45.64)  (3.06)  (339.63)  (419.68)earnings (loss) pershare (NOK)Net cash flow in the (41.1) 82.1 237.3 113.2 87.8periodCash position end of  399.2  187.2  399.2  187.2  161.8period Presentation and Webcast Details A presentation by BerGenBio’s senior management team will take place at 9.00 am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Bjørvika The presentation will webcast live and the link will be available at in the section Investors/Reports and presentations/Webcasts. A recording will be available shortly after the webcast has finished. The results report and the presentation will be available at in the section: Investors/Reports and presentations from 7:00 am CET the same day. -End- About BerGenBio ASA   BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the essential role of Axl kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive solid and haematological cancers. BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated in the second half of 2018. It is the only selective Axl inhibitor in clinical development. The Company sponsored clinical trials are: · BGB324 as a single agent and combination therapy in acute myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS) · BGB324 with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small cell lung cancer (NSCLC) · BGB324 with KEYTRUDA in advanced adenocarcinoma of the lung, and · BGB324 with KEYTRUDA in triple negative breast cancer (TNBC). The clinical trials combining BGB324 with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc., Kenilworth, N.J., USA. In addition, a number of investigator-sponsored trials are underway, including a trial to investigate BGB324 with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining BGB324 with docetaxel in advanced NSCLC. BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with BGB324. This will facilitate more efficient registration trials and support a precision medicine based commercialisation strategy. The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-Axl monoclonal antibody.  For further information, please visit:  KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc. Contacts   Richard Godfrey CEO, BerGenBio ASA +47 917 86 304 Tom Henrik Sundby Finance Director, BerGenBio ASA +47 477 54 415 Media Relations David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson  +44 207 638 9571 Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

THQ Nordic acquires Biomutant® developer Experiment 101

Biomutant is an open world, post-apocalyptic kung-fu fable action role-playing game. The game was first announced at Gamescom in August 2017, receiving strong reception with fans and the gaming media. The total consideration paid for all shares is SEK 75.3 million paid to the sellers Goodbye Kansas and Stefan Ljungqvist[1] . SEK 10.0 million of the consideration is paid by issuance of new THQ Nordic B shares, with a 3-year lock-up, to Stefan Ljungqvist1, subject to decision by the next general meeting in THQ Nordic. The remaining consideration is paid in cash upon closing. The parties have agreed an earnout based on Biomutant´s financial performance. The earnout will be calculated as a small percentage of THQ Nordic’s net proceeds from Biomutant during the first 36 months after release, after deduction of 150% of both total consideration paid and game development costs. The consideration paid will mainly be booked in the group balance sheet as ongoing game development as well as IP rights for the Biomutant franchise. Lars Wingefors comments: “We saw significant potential in Experiment 101 and Biomutant, under Stefan Ljungqvist’s leadership, early in the development 2016. After the strong reception Biomutant received at its announcement at Gamescom 2017, we are excited to have been able to acquire Experiment 101 and Biomutant. Our aim is to build Biomutant into one of our major franchises. The recruitment of Stefan Ljungqvist and his talented team brings important new power to THQ Nordic. In addition to continue leading the Biomutant franchise, Stefan will advise on our strategy, future acquisitions and further game development projects.” ---------------------------------------------------------------------- [1]  To Stefan Ljungqvist´s wholly-owned company Boston Front AB 

Ambea interim report January-September 2017

CEO comment: ”In the third quarter, we continued to see positive results from our strategy, which is to grow the number of our Own Management units both by opening new residential care units and through acquisitions. During the quarter, we opened two new LSS residential care units in Sweden one new unit in Norway, and completed one acquisition in each market. Our organic growth in Norway is proceeding well, but the weak tender market in Sweden and the supported living units that were closed down – and for which we are still awaiting permits – are posing a challenge. Net sales for the quarter amounted to SEK 1,488 million (1,376) and adjusted EBITA, excluding items affecting comparability, rose 4 per cent to SEK 184 million (177). Sales growth of 8 per cent was driven by growth in Own Management which, in turn, was attributable to acquisitions and start-up units. In the third quarter, the Contract Management market continued to weaken due to few new tendering processes while interest in Own Management remained high. We saw a favourable trend in staffing operations during the quarter, with positive contributions to sales growth by Rent a Nurse and Careteam, in particular”. Highlights of the third quarter: · Net sales rose 8 per cent to SEK 1,488 million (1,376) · Operating profit (EBIT) increased to SEK 169 million (145) · EBITA increased 12 per cent to SEK 184 million (164), corresponding to a margin of 12.4 per cent (11.9) · Adjusted EBITA, excluding items affecting comparability of SEK 0 million (-13), increased 4 per cent to SEK 184 million (177). The adjusted EBITA margin was 12.4 per cent (12.9) · Profit for the period was SEK 119 million (87) · Earnings per share before and after dilution totalled SEK 1.75 (1.34) · Operating cash flow amounted to SEK 57 million (102) · Free cash flow totaled SEK 49 million (98) Telephone conference: Ambea will host a presentation with the possibility to attend through a telephone conference at 10:00 (CET) today. The presentation will be held in English and will also be available as webcast on: Dial-in information: To ensure that you are connected to the conference call, please dial in a few minutes before the conference call to register your attendance by stating “Ambea”. Sverige:                              +46 (0) 8 5065 3938Storbritannien:                    +44 (0) 20 3427 1904 USA:                                   +1646 254 3361 The interim report, presentation and other material are available on For more information, contact: Louise Tjeder, Director IR and StrategyTelephone: +46 731 43 17 68E-mail: Nanna Wedar, Communications DirectorTelephone: +46 70 166 58 88E-mail: This information is information that Ambea AB (publ.) is obliged to make public pursuant to the EU  Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, on November 17, 2017.    Ambea, is present in care services, and has approximately 14,000 employees. We offer services in disabled care, individual and family care, and elderly care with a focus on residential care and own management. We aim to be the quality leader in all that we do and our vision is to make the world a better place, one person at a time. As of December 31, 2016, Ambea had approximately 6,200 beds and 1,300 school-/daily activity-placements in around 460 units across Sweden and Norway. Total revenue and adjusted EBITA for the 2016 financial year amounted to SEK 5,409 million and SEK 456 million, respectively. The company was founded in 1996, is headquartered in Solna and is listed on Nasdaq Stockholm.

Hiddn Solutions ASA - Mandatory notification of trade

Reference is made to the announcement made on 16 November 2017 by Hiddn Solutions ASA (the "Company") in connection with a successfully private placement of NOK 7,500,000 million in new shares. Dallas Asset Management AS, a company controlled by Jan Opsahl, board member in the Company, has been allocated 1,000,000 shares in the Company. Following the completion of the private placement, Dallas Asset Management AS will hold 3,200,000 shares (4.29%) in the Company. Wollebekkgruppen AS, a company 50 % owned by Carl Espen Wollebekk, CEO, has been allocated 100,000 shares in the Company. Following the completion of the private placement, Wollebekkgruppen AS will hold 100,000 shares (0.13%) in the Company. Finn Clausen Gruppen AS, a company 50 % owned (indirectly through Wollebekkgruppen AS) by Carl Espen Wollebekk, CEO, has been allocated 250,000 shares in the Company. Following the completion of the private placement, Finn Clausen Gruppen AS will hold 4,250,000 shares (5.7%) in the Company. Intelco Concept AS, represented in the Company’s board by chairman Øystein Tvenge, has been allocated 750,000 shares in the Company. Following the completion of the private placement, Intelco Concept AS will hold 10,605,969 shares (14.22%) in the Company. Øystein Tvenge, chairman, has been allocated 750,000 shares in the Company.  Following the completion of the private placement, Øystein Tvenge will hold 1,132,271 shares (1.52%) in the Company All of the above transactions were made at a price of NOK 2 per share.  -- This information is subject of the disclosure requirements pursuant to section 5-12 cf. 4-2 of the Norwegian Securities Trading Act.

Lactobacillus reuteri reduced bone loss in older women

Lactobacillus reuteri ATCC PTA 6475 is a naturally occurring bacteria in the gastrointestinal tract of humans and has been shown to have beneficial effects on bone in animals. In a randomized controlled trial conducted at the University of Gothenburg, 75 to 80-year-old women with low bone density received supplementation of Lactobacillus reuteri ATCC PTA 6475 or placebo for one year. In the group supplemented by Lactobacillus reuteri the loss in bone density was halved compared to placebo. Detailed results will be published in a scientific journal.  “This trial provides the first evidence that age-dependent bone loss can be reduced with probiotic supplementation, which could emerge as a novel approach to prevent osteoporosis” says Professor Mattias Lorentzon at the University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden. “Up to 50 percent of older women are affected by fractures. The fact that Lactobacillus reuteri ATCC PTA 6475 was shown to reduce bone loss in this group is therefore very promising. We hope that further studies will confirm the results, so that this new way of maintaining good bone health in old age can be of use”, says Axel Sjöblad, Managing Director, BioGaia. Latest press releases from BioGaia2017-11-07 BioGaia’s probiotic shown to promote growth and prevent recurrent diarrhea2017-10-25 BioGaia AB – Interim management statement January 1 – September 30, 2017 2017-08-18 BioGaia AB – Interim report 1 January – 30 June 2017  This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 AM CET on 17 November 2017.  

Hansa Medical's Nomination Committee for the AGM 2018 appointed

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of chairman of the Annual General Meeting, election of auditors (if applicable) and the auditors and proposals for rules for the Nominating Committee for the AGM in 2018. The Annual General Meeting of Hansa Medical AB (publ) will be held May 29, 2018 in the Auditorium (Hörsalen) by the company's premises at Scheelevägen 22 in Lund. Shareholders wishing to submit comments or submit proposals to the Nomination Committee may do so no later than 29 March 2018 via email to or by letter to Hansa Medical, Nomination Committee, Box 785, 220 07 Lund, Sweden. The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website. Financial calendarYear-end report 2017                                        14 February 2018Annual report 2017                                            11 April 2018Interim report for January – March 2018           25 April 2018Annual General Meeting                                    29 May 2018Interim report for January – June 2018             19 July 2018Interim report for January – September 2018   1 November 2018 This information is such information that Hansa Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 am CET on 17 November 2017.

Internationella Engelska Skolan 2017/2018 Interim Report - (1 July - 30 September 2017)

Progress of operations in the quarter (July-September) · Four new schools opened in August—IES Helsingborg, IES Landskrona, IES Södertälje and IES Årsta—with 55 classes and some 1,600 students. · The number of students in the Swedish operation at the end of the quarter was 23,911 (21,463), an 11.4% increase on the corresponding point of the previous year. · There were around 154,000 registrations on waiting lists at the end of the quarter, an increase of some 32,000 registrations on the corresponding point of the previous year. · Total operating income increased by 18.5% year on year, mainly due to a larger student base. · Adjusted EBIT for the quarter increased by 4.9% on the corresponding quarter of the previous year, amounting to MSEK 37.9 (36.1). Accordingly, the adjusted operating margin was 7.7% (8.7). · MSEK 13.0 of the change in total operating income and adjusted EBIT is due to a revised assessment, whereby the applicable components of central government subsidies for Lärarlönelyftet and Karriärtjänster were recognized in Q1 this year, while they were not recognized until Q2 in the previous year. · Profit for the quarter was MSEK 26.0 (23.0) and earnings per share were SEK 0.65 (0.58). · Cash flow from operating activities amounted to MSEK 43.9 (87.8). · Ralph Riber left his position as CEO and President effective 7 August. IES’s CFO Fredrik Åkerman became Interim CEO and President effective the same date. Significant events after the end of the reporting period  · Subsequent to appeal at administrative court and addenda to the original application, on 4 October, IES received new permits from the Swedish Schools Inspectorate to start up and operate another five schools with F-9 preschool and compulsory school operations, and new permits to extend current operations at two existing compulsory schools with F-3 grades.  · On 16 October, IES was informed that its largest shareholders had decided to reorganize their collective shareholdings in IES on the same date. After this reorganization, according to the information IES has received, TA Associates LLP would indirectly hold some 49.89%, Barbara Bergström would indirectly hold 19.23%, members of the current and previous managements would hold 2.13%, while other shareholders would hold 28.75% of the shares and votes of IES. CEO’s statementThe first quarter began as planned with our four new schools in Helsingborg, Landskrona, Södertälje and Årsta opening to 1,600 students. Accordingly, including the expansion of our other schools, we increased the number of classes from 711 in the previous academic year to 798 in the current one, and our student base by over 11%.Total operating income was up by 18.5%, mainly as a result of this larger student base, but also because for accounting reasons to some extent, where the Lärarlönelyftet and Karriärtjänster government subsidies in Q1 were allocated differently in the corresponding quarter of the previous year.This accounting change also affected adjusted EBIT, which rose by 4.9% to MSEK 37.9, equivalent to an adjusted EBIT margin of 7.7%. Excluding the effects of the above accounting change, revenue per student increased by 3.5%.Total personnel expenses per student adjusted for the expense affecting comparability for the former CEO’s departure, increased by 7.3%. Current progress on the labor market, where the shortage of qualified teachers is causing increased wage creepage, could reasonably be assumed to affect municipal school budgets, and thus put upward pressure on school voucher funding, retroactively for 2017, and in tandem with each municipality setting its school voucher funding for the forthcoming calendar year. This is something we will be monitoring closely and carefully to ensure that municipal costs for compulsory school operations are fully reflected in school voucher funding.Meanwhile, it is positive that our expenses per student excluding personnel expenses were unchanged year on year, excluding start-up costs for our new schools. Here, the positive effects of economies of scale are clearly apparent in our business, with centralized contracts and efficient central administration.It is a relief to finally put the issue of IES’s application for new school permits behind us. After having appealed against the Swedish Schools Inspectorate’s rejection and supplemented our applications, all of our permits have now been granted. The two planned schools, in Sundbyberg and Huddinge (Länna), are scheduled to open in August 2018, and based on a large number of permits, we are maintaining concrete dialogues on future start-ups with the large number of municipalities that want IES’s profile and quality.Our joint venture in Spain is continuing to make positive progress, with somewhat larger student cohorts this year. However, revenues are low for seasonal reasons in our first quarter, which caused a small loss in this business. We are now working actively on plans for acquisition-led expansion in Spain to supplement Elians’ three current schools.Our two COOs, with management responsibility for our schools, took up position at the beginning of the term. Their focus is on quality, but they are not responsible for profitability. Both have successful backgrounds as IES principals. In their new roles, they will be supporting our school principals in continuing to enhance the quality of our operations, serving as sounding boards and a link between the rest of our Group Management and operations.The fact that the number of waiting list registrations rose in the period, and now stands at 154,000, is satisfying. It shows that students and parents that want to give their children the opportunity of attending a high-quality bilingual school with high ambitions and an orderly environment appreciate our work focused on quality. We’re also delighted that so many new municipalities, in a period of high-growth in youth populations in Sweden’s urban areas, are showing an interest in offering their residents IES schools as an alternative to their other schools. Fredrik ÅkermanCEO For more information, please contact:Johan Hähnel, Investor Relations, tel. +46 (0)70 605 6334, Fredrik Åkerman, Interim CEO, tel. +46 (0)70 415 2365. Teleconference in connection with publication of the quarterly report:On Friday 17 November at 10:00 a.m. CET, Fredrik Åkerman, Interim CEO, will hold a conference call for the publication of the quarterly report. The call will be held in English. To participate, please call the following number: +46 (0)8 566 42651 and enter the code: 98067875#. The presentation will be uploaded to IES’s website before the conference call, at:  Reporting schedule   Annual General Meeting 2016/17 – 17 November 2017Interim Report Q2 2017/18 – 22 February 2018Interim Report Q3 2017/18 – 25 May 2017Year-End Report 2017/18 – 29 August 2018 Internationella Engelska Skolan i Sverige Holdings II AB discloses the information provided herein pursuant to the EU’s Market Abuse Regulation. The information was submitted for publication, through the agency of the above contacts, on 17 November 2017 at 08:00 a.m. CET.

Notice to attend the Extraordinary General Meeting of DDM Holding AG

A.  Agenda and Proposal 1.   Election of a new Board Member The board of directors of the Company (the Board of Directors) proposes that Mr. Mikael Nachemson be elected as a new member of the Board of Directors for a term of office expiring upon completion of the next annual general meeting. Mr. Nachemson has previously been CEO of Bure Equity, AB Custos and E. Öhman J:or AB, and he has also held board positions with a large number of listed and private companies. Mr. Nachemson has solid experience from the finance industry and is currently Chairman of the Board of Påmind AB, a company that he also founded. Mr. Nachemson is a Swedish citizen and graduated from the Stockholm School of Economics. B.  Participation and Voting Rights Shareholders registered with voting rights in the share register as of the close of business on 8 December 2017, will be authorized to participate and to vote at the EGM. From close of business on 8 December 2017 up to and including 18 December 2017, no entries will be made in the share register which would create a right to vote at the EGM. Shareholders who sell part or all of their shares before the EGM are no longer entitled to vote to that extent. Such shareholders are required to exchange their admission card and voting material to reflect the change in their shareholding. Shareholders who wish to participate or be represented at the EGM may either download the registration form via our website or request a physical copy by e-mail to The registration form should be completed and returned by mail or e-mail to the following address: Computershare Schweiz AG, General meetings, P.O. Box, 4601 Olten, Switzerland; e-mail: as soon as possible but in any case no later than 14 December 2017. Upon receipt of their registration form shareholders will be provided with an admission card and voting material (including proxy form) for the EGM. Shareholders (i) whose shares are registered in accordance with the Articles of Association of the Company in a securities register in accordance with the Swedish Financial Instruments Accounts Act (1998:1479) or otherwise in accordance with Swedish law and (ii) who hold such shares through a nominee must, in order to be entitled to attend and vote (in person, representation by proxy or by the Independent Proxy) at the EGM, temporarily register the shares in their own name. For the shares to be re-registered in time, such shareholders should instruct the nominee that manages the shares well in advance of 8 December 2017 for temporary re-registration, so called voting registration. After such shares have been registered in the shareholder’s own name, the shareholder shall follow the instructions as set out above in this section. C. Representation Shareholders who do not intend to participate personally at the EGM may participate and vote at the meeting through the representation of: - the independent proxy, or - a third person who need not be a shareholder. Mr. Florian S. Jörg, attorney-at-law, c/o Bratschi Wiederkehr & Buob AG, Zürich, Switzerland, has been elected at the ordinary general shareholders’ meeting held on 31 May 2017 as the independent proxy of the Company and will thus serve as independent proxy for the EGM. Shareholders opting to be represented by the independent proxy shall submit the original of the completed and signed power of attorney (incorporated in the voting material) with voting instructions to Computershare Schweiz AG, General meetings, P.O. Box, 4601 Olten, Switzerland, by no later than 14 December 2017. Shareholders may also vote by issuing electronic proxy and voting instructions to the independent proxy by voting through the online proxy voting platform until 17 December 2017, 11:59 am CET. Further details can be found on our website To the extent that a shareholder opts to be represented by the independent proxy but does not give the independent proxy specific voting instructions, the independent proxy will vote as proposed by the Board of Directors. If shareholders opt to be represented by a third person, their completed and signed original power of attorney (incorporated in the voting material) as well as their admission card and voting material should be sent directly to the address of their designated representative. D.  Shares and votes As of the date hereof, the share capital of the Company amounts to CHF 13’560’447, divided into 13’560’447 fully paid-in registered shares with a nominal value of CHF 1.00 each and thus a total of 13’560’447 votes. As of the same date, the Company does not directly or indirectly hold treasury shares. DDM Holding AG 17 November 2017, for the Board of Directors Kent Hansson Chairman This is information which DDM Holding AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 17 November 2017.

Serneke to build 160 rental apartments in Årsta

The project, located within the Sävlången 2 and Idlången 3 properties, is part of the so-called Årstastråket area, where the City of Stockholm plans to create some 3,000 new homes for 7,500 inhabitants over a period of at least ten years in a central and attractive location, with good access to public transport, recreation opportunities and services. In addition to housing, the contract includes a preschool with four sections, a garage with 45 parking spaces beneath an open courtyard and a number of complementary buildings. “The project is completely in line with our desired project portfolio, in which we are focusing on public housing and private property companies that manage their properties over an extended period of time. It feels really satisfying to once more gain the trust of Stockholmshem and to be involved in construction that reduces the housing shortage in Stockholm,” says Niklas Wirström, Construction Manager at Serneke Construction East. Planning will commence in December 2017 and the project will continue until the second quarter of 2021. The order value of approximately SEK 330 million will be included in order bookings for the fourth quarter of 2017. For additional information, please contact: Daniel Åstenius, President, Serneke ConstructionTel: +46 70 813 79 Niklas Wirström, Construction Manager, Serneke ConstructionTel: + 46 70 379 68 Johan Live, Press OfficerTel: +46 768 68 11 This information is such that Serneke is required to disclose under the EU Market Abuse Regulation. The information was submitted under the auspices of the contact persons stated above, for publication on November 17, 2017, at 8.00 a.m. CET.  Serneke is a rapidly growing corporate group active in construction, civil engineering, project development and property management. The Group was founded in 2002 and today has income of nearly SEK 5 billion and nearly 1,000 employees. Through novel thinking, the Company drives development and creates more effective and more innovative solutions for responsible construction. The Company builds and develops housing, commercial buildings, industrial facilities, public buildings, roads and civil engineering projects, and other infrastructure. The Company’s customers are public and commercial clients, and operations are focused on the three metropolitan regions in Sweden, Gothenburg (Region West), Stockholm (Region East) and Malmö (Region South). Serneke’s headquarters are located in Gothenburg and the Company also has offices in Stockholm, Malmö, Helsingborg, Borås, Halmstad, Strömstad, Trollhättan, Varberg and Alingsås. The Company’s Series B shares (SRNKE) have been listed on the Nasdaq Stockholm exchange since November 2016.Further information about Serneke Group AB is available at

InDex Pharmaceuticals Holding AB (publ) interim report January – September 2017

Period July – September 2017 ·  Revenues amounted to SEK 0.0 (0.0) million ·  Operating result amounted to SEK –13.3 (–6.6) million ·  Result after tax amounted to SEK –13.1 (–7.4) million, corresponding to SEK –0.21 per share (–0.25) before and after dilution ·  Cash flow from operating activities amounted to SEK –16.6 (–7.5) million  Period January – September 2017 ·  Revenues amounted to SEK 0.1 (0.1) million ·  Operating result amounted to SEK –50.7 (–23.2) million ·  Result after tax amounted to SEK –50.4 (–24.9) million, corresponding to SEK –0.81 per share (–0.83) before and after dilution ·  Cash flow from operating activities amounted to SEK –54.1 (–3.3) million ·  Cash and cash equivalents at the end of the period amounted to SEK 139.1 (3.7) million ·  Number of employees at the end of the period was 7 (7) ·  Number of shares at the end of the period was 62 528 433 All comparative amounts in brackets refer to the outcome of InDex overall activities during the corresponding period 2016. Significant events during July – September 2017 ·  A new patent for cobitolimod has been granted in Europe ·  Orphan-drug designation for cobitolimod for pediatric ulcerative colitis has been received in the US ·  A new patent for cobitolimod has been granted in Japan Significant events after the reporting period ·  A new patent for cobitolimod has been issued in the US ·  InDex participated with a poster presentation at the United European Gastroenterology Week (UEGW) 2017 “The work with the CONDUCT study is now entering the next phase, in which all activated clinics should recruit their first patients as soon as possible,” said Peter Zerhouni, CEO of InDex Pharmaceuticals.  CEO statementWe are now at the end of the start-up phase for the CONDUCT study, which is InDex’s main focus. The study is currently approved in 10 of the 12 planned countries. Two thirds of the selected 90 clinics have been activated and can enroll patients. The patient recruitment is proceeding according to plan. The objective to have top line results from the study in the fourth quarter of 2018 remains. The work with CONDUCT is now entering the next phase, in which all activated clinics should recruit their first patients as soon as possible. The study is open for patients with left-sided moderate to severe active ulcerative colitis. As it is a disease with both active and inactive periods, one must wait until a patient is in an active period before it can qualify to participate in the study. It is more common with active periods during the winter months. InDex employees have visited 25 of the clinics to build on the team spirit from the investigators’ meeting that InDex hosted in Stockholm in March. We see a strong commitment to the study and have had a very positive impression of the clinics during our visits. The same applies to the contract research organization’s local staff who manages the day-to-day contact with the clinics, so-called CRAs. In December, we will gather the CRAs from all the countries again in Stockholm to discuss recruitment strategies and to let them exchange best practices. At the end of October, we also met several of the investigators in the study at UEGW, the annual major European conference for gastroenterologists. The big topic of conversation at the conference was the news that the large US company Celgene has discontinued the development of the substance mongersen due to lack of efficacy in a Phase III study in Crohn’s disease. Mongersen is an oligonucleotide like cobitolimod, but the substances have completely different mechanisms of action, so the news does not affect our assessment of cobitolimod’s chance of success. Since the summer, the patent situation for cobitolimod has been further strengthened through one new use patent in Europe, one in Japan and one in the US. I particularly would like to highlight the US patent as a valuable complement to our existing patent portfolio, as it covers the use of cobitolimod for treatment of ulcerative colitis in patients without a history of steroid use when cobitolimod is not administered in combination with steroids. I look forward to presenting our progress in the CONDUCT study and other areas at the Redeye Life Science Seminar on November 24, where I hope to meet new and old shareholders.  For more information:Peter Zerhouni, CEOPhone: +46 8 508 847 35E-mail: PublicationThis information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on November 17, 2017. InDex Pharmaceuticals in briefInDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit

Notice of extraordinary general meeting in ChromoGenics

  NOTICE OF EXTRAORDINARY GENERAL MEETING IN CHROMOGENICS AB (PUBL) The shareholders in ChromoGenics AB (publ) reg. no. 556630-1809 (the “Company”) are hereby convened to the extraordinary general meeting on Friday 15 December 2017, at 13:00 at Advokatfirman Lindahl’s office on Vaksalagatan 10, Uppsala. Notification etc. Shareholders who wish to participate at the extraordinary general meeting must: - on Saturday 9 December 2017 be registered in the share register kept by Euroclear Sweden AB (note that the record date is a Saturday, and therefore the shareholders must be registered in the share register at the latest on Friday the 8 December 2017), and - notify his or her intention to attend the extraordinary general meeting by mail to Ullforsgatan 15, 752 28 Uppsala stating “extraordinary general meeting”, by telephone to 018-43 00 430 or by e-mail to at the latest Wednesday 13 December 2017. Such notification shall include the shareholder’s name, personal identification number or corporate registration number (or similar), address and daytime telephone number, number of shares, details on advisors if any, and where applicable, details of representatives or proxies. Nominee-registered shares To be entitled to participate in the general meeting, shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names in the share register maintained by Euroclear Sweden AB in order to be entitled to attend the general meeting. Such registration must be duly effected in the share register on Friday 8 December 2017 (since the record date is a Saturday), and the shareholders must therefore advise their nominees well in advance of such date. Proxy Shareholders represented by proxy must submit a dated proxy. If the proxy is executed by a legal person, a certified copy of the certificate of registration or equivalent must be attached. The proxy may not be valid for a period longer than five years from its issuance. The original proxy and certificate of registration should be submitted to the Company by post at the address mentioned above in due time prior to the general meeting. The Company provides a form of proxy at request and it is also available at the Company’s website, Number of shares and votes As of the date of this notice, there are a total of 23 214 326 shares in the Company. The total number of votes are 23 214 326. Proposed agenda 1.Opening of the general meeting and election of chairman of the general meeting 2.Preparation and approval of the voting list 3.Election of one or two persons to verify the minutes 4.Approval of the agenda 5.Determination as to whether the meeting has been duly convened 6.Decision regarding adoption of new Articles of Association  7.Resolution regarding approval of the Board’s decision to issue new so-called units, with pre-emption rights for existing shareholders  8.Closing of the general meeting Item 1 – Opening of the general meeting and election of chairman of the general meeting Advokat Mattias Prage is proposed as chairman of the general meeting. Item 6 – The board’s proposal for decision regarding adoption of new Articles of Association In order to enable the issuance of units with pre-emption rights in accordance with item 7 of the agenda the board proposes that the shareholders’ meeting resolves to amend the articles of association regarding the limits of the Company’s share capital and the number of shares (§ 4 and § 5) in accordance with the following: +----------------------+----------------------------------------------+|Current wording |Proposed wording |+----------------------+----------------------------------------------+|§ 4 The share capital |§ 4 The share capital shall amount to at least||shall amount to at |SEK 4,000,000 and no more than ||least |SEK 16,000,000. ||SEK 1,800,000 and no | ||more than | ||SEK 7,200,000. | |+----------------------+----------------------------------------------+|§ 5 The number of |§ 5 The number of shares in the company ||shares in the company |shall be at least 20,000,000 and not more ||shall be at least |than 80,000,000. ||9,000,000 and not more| ||than | ||36,000,000. | |+----------------------+----------------------------------------------+                                                         For a valid resolution on the adoption of new articles of association, the proposal must be supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the meeting. Item 7 – Resolution regarding approval of the Board’s decision to issue a new issue of shares, so-called units, with pre-emption rights for existing shareholders The board of directors, resolved on 16 November 2017, subject to approval by the general meeting, to issue so called units with pre-emption rights for existing shareholders on the main terms set out below. The board’s resolution implies that the Company’s share capital may be increased with not more than SEK 9 285 730,90 (of which SEK 4 642 865,45 are attributable to increase due to issue of shares and SEK 4 642 865,45 are attributable to increase due to issue of warrants) by an issue of not more than 23 214 326 new so called units on the terms and conditions set out below: Each unit consists of one (1) newly issued share in the Company and one (1) newly issued warrant in the Company of series 2017/2020. This means that a maximum of 23 214 326 new shares and a maximum of 23 214 326 new warrants may be issued. The right to subscribe for new units shall belong to those persons who on the record date for the new issue of units are recorded as shareholders of the Company, where one (1) existing share shall entitle to one (1) unit right and one (1) unit right shall entitle to one (1) unit. In the event that all new units are not subscribed for with pre-emption rights the board of directors shall, within the limit of the maximum number of units to be issued, resolve on allocation of units that are not subscribed for with pre-emption rights. Such allocation shall firstly be made to subscribers that have used subscription rights in the issue in relation to the amount of subscription rights that each subscriber has used to subscribe for new units and secondly to other subscribers in relation to subscribed amount, and if this cannot be made, through drawing of lots. To ensure that shares arising through subscription by virtue of warrants issued by the Company, shall give right to participate in the new unit issue, the subscription must be executed not later than the date set out in the terms of the warrants. If full subscription for new shares takes place by use of outstanding warrants the resolution on new issue of units shall mean that the company’s share capital shall be increased further by not more than SEK 9 372,80051 through a new issue of not more than an additional 23 432 units. The record date for participation in the new issue of shares shall be 4 January 2018. The new units are issued at a subscription price of SEK 1.75 per unit which corresponds to a subscription price of SEK 1.75 per share. The warrants are issued free of consideration. Subscription with pre-emption rights shall be made by cash payment during the period from 8 January 2018 to 22 January 2018. Subscription without pre-emption rights shall be made on a subscription list during the same period. Payment for units subscribed for without pre-emption rights shall be made by cash payment in accordance with instruction on a contract note which will be sent to those who have been allotted units. The board of directors shall have the right to extend the subscription and payment period. The new shares entitle to dividends for the first time on the first record date for dividend that take place after the issue of new shares has been registered with the Swedish Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB. Each one (1) warrant entitles to subscribe for one (1) new share in the Company for SEK 3.50 (exercise price). Subscription of shares upon exercise of the warrants shall be made in accordance with the term and conditions for the warrants during the period from 10 January 2020 to 31 January 2020. After 31 January 2020 the warrants shall not entitle to subscription. In addition, customary terms and conditions shall apply in relation to the warrants. A new share that has been issued by virtue of a warrant entitles to dividends for the first time on the first record date for dividend that take place after the subscription of new shares has been registered with the Swedish Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB. The resolution on new issue of units is subject to approval by the general meeting and requires that the company’s articles of association are amended. The managing director, or any other person appointed by the board of directors, shall have the right to take those smaller measures that may be required in order to register the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB. Information at the Extraordinary General Meeting The board of directors and the managing director shall, upon request by any shareholder and where the board of directors determines that it can be done without material harm to the Company, provide information of circumstances which may affect the assessment of a matter on the agenda. Documentation The board of directors’ complete proposal under items 6-7 above as well as other documents according to the Swedish Companies Act will be held available at the Company’s office (address above) and on the website not later than two weeks before the meeting, i.e. not later than Friday 1 December 2017. The documents will also be sent, without charge, to shareholders who so request and inform the Company of their postal address. The documents will also be held available at the extraordinary general meeting.  Uppsala in November 2017 ChromoGenics AB (publ) The board of directors Contact:Thomas Almesjö, CEOSusanne Andersson, CFO & Head of CommunicationsTel: +46 18 430 0430E-mail:  This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on November 17, 2017.  Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation. About ChromoGenicsChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started commercial sales to real estate projects in Scandinavia. ChromoGenics is located in Uppsala and has about 20 employees. The technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.

IK expands its small cap strategy to the Benelux region - Hires Sander van Vreumingen as Benelux Small Cap partner

IK has been present in the Benelux region since 1995 and has invested over €1bn into thirteen successful investments during this time. Within the mid cap space, IK has been one of the most active regional players with notable transactions including Vemedia, the market leader of OTC drugs, Magotteaux, the leading manufacturer of cast wear parts for the cement and mining industries and fund administrator Vistra, amongst many others. As IK now extends its small cap strategy, Sander van Vreumingen has been appointed partner and responsible for the Benelux Small Cap team. Sander joins from Gimv, where he worked for over a decade, and prior to that at the Dutch investment firm Halder. He has substantial experience in the small cap segment, and has been involved in numerous transactions, including Mackevision, ALT, Arplas, Walkro, BMC, Oldelft, ARS Traffic & Transport Technology, Hebu and Geveke. Sander holds an MSc in Economics from Erasmus University Rotterdam. IK’s Amsterdam office, which was established earlier this year, is led by Remko Hilhorst, Partner responsible for IK’s Mid Cap Benelux team. Remko Hilhorst has been with IK since 2001. Together, IK’s Small and Mid Cap teams will focus on investments with enterprise values of up to €500m, partnering with entrepreneurs who are looking for support to help them achieve the next stage of their company’s growth and development. “Having both a mid cap and small cap practice operating on the ground will allow the firm to capitalise on the synergies which are present in the market and give the teams a superb investing platform from which to execute transactions,” said Remko Hilhorst, Partner at IK Investment Partners. “Benelux is an important market for IK, offering many interesting investment opportunities in various sizes and sectors. Sander, with his wealth of experience and wide network of contacts in the region, is a great addition to our team to reinforce our strong position in Benelux. We are delighted to welcome him to the firm,” said Christopher Masek, Partner and CEO at IK Investment Partners. “I am very pleased to join one of the most reputable private equity firms in the Benelux region. I look forward to working closely with Remko and the mid cap team whilst establishing a dedicated small cap team, in order to further enhance the firm’s existing success,” said Sander van Vreumingen, Partner at IK Investment Partners. 

EQT Infrastructure acquires Dutch telecom and infrastructure company CAIW

· EQT Infrastructure to acquire CAIW, owner and operator of telecom infrastructure connecting more than 350,000 households in the Netherlands · EQT Infrastructure is committed to actively support CAIW in further strengthening its market position and investing in growth opportunities · CAIW to be included in the same holding as DELTA headed by Marco Visser as CEO The EQT Infrastructure III fund (“EQT Infrastructure”) has signed a definitive agreement to acquire CIF Holding B.V. (”CAIW” or “the Company”) from Rabo Bouwfonds Communication Infrastructure Fund C.V.. CAIW is a leading regional telecom infrastructure company in the Netherlands owning and operating a state-of-the-art fiber and coax network, connecting more than 350,000 households. CAIW employs approximately 210 people and generated sales of EUR 112 million in 2016. EQT Infrastructure will invest in the continued development of CAIW’s growth strategy while strengthening its market position and exploring opportunities to expand its existing fiber network. “EQT Infrastructure looks forward to supporting CAIW’s growth journey in the Dutch telecom and infrastructure market. Following last year’s investment in the telecom infrastructure company DELTA, the acquisition of CAIW fortifies EQT Infrastructure’s commitment to the Dutch fiber segment”, says Matthias Fackler, Partner at EQT Partners and Investment Advisor to EQT Infrastructure. Joost Goderie, Senior Managing Partner at Rabo Bouwfonds Communication Infrastructure Fund: ‘With support of institutional investors, we have developed large-scale fiber networks in different areas of the Netherlands. We are especially proud that CAIW successfully rolled out optical fiber to municipalities and households in rural areas. Welcoming EQT Infrastructure as the new investor will guarantee continuity of CAIW’s services and shape the ambitions for the future.” EQT Infrastructure intends to include CAIW in the same holding as DELTA and the new group management structure will oversee all activities related to both CAIW and DELTA. It will be headed by Marco Visser, current CEO of DELTA. The transaction is subject to customary conditions, such as completion of a works council consultation procedure and approval of the Autoriteit Consument & Markt (ACM). The parties have agreed not to disclose financial details related to the transaction. The transaction is expected to close in Q4, 2017. Morgan Stanley acted as sole financial advisor and Clifford Chance as legal advisor to EQT Infrastructure. Contacts:Matthias Fackler, Partner at EQT Partners, Investment Advisor to EQT Infrastructure, +49 89 2554 99 505EQT Press Office, +46 8 506 55 334 About EQTEQT is a leading alternative investments firm with approximately EUR 37 billion in raised capital across 24 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: About CAIWCAIW is a telecom infrastructure company in the Netherlands that owns and operates broadband connections to more than 350.000 households and businesses. In recent years, CAIW rolled out fiber networks to municipalities and homes in remote areas. CAIW is also a strong regional internet service provider offering broadband, TV and telephony services. Westland, Schiedam and Almelo are amongst the largest regions in CAIW’s footprint. More info: 

Coor upgrades digital interface for superior customer experiences

With the aim of enhancing the customer’s experience and increasing availability, Coor has executed dedicated initiatives to enhance its largest digital customer platforms. Coor Service Portal is a customer portal that many of its customers use Nordic wide. The portal is fully responsive and embedded in a responsive cloud-based solution that is easily accessible from all types of device (PCs, tablets and mobiles). It enables Coor’s end-users to find information, manage cases, place orders or make bookings. The portal is linked to Coor’s CRM system, which supports automated workflows and makes cases fully traceable. FOOD by Coor Portal is a dedicated restaurant portal. Apart from menu information, it also has functionality to order food and related products to take away. “As the leading service provider in the Nordics, it’s important that we have a good understanding of how to use new technology on our deliveries. The ability to offer our customers really good, state-of-the-art customer platforms is part of these efforts. Users should experience Coor as a provider that adds value, which these platforms contribute to,” commented Rikard Wannerholt, Coor’s Head of Operational Development & Transformation. Both platforms have gone live in parts of Coor’s business, and will be rolled out during 2017. For more information, images etc., please visit or contact: Rikard Wannerholt, Head of Operational Development and Transformation+46 10 559 59 35, Sofie Schough, acting Communictions Director+46 10 559 59 83, 

Catella establishes fund manager Catella Residential Investment Management

Since January 2016 Catella Real Estate AG built up a strong team of residential portfolio managers in Berlin, led by Xavier Jongen and Michael Keune. The team manages two mutual property funds and three special property funds. The total invested capital in the five funds amounts to EUR 1.3 billion and so far the funds have made investments in 8 countries in Europe; Germany, Netherlands, Denmark, Spain, France, UK, Poland and Austria. The decision to establish CRIM is another step in Catella’s ambition to build and develop strong and specialized competence centres that manage European residential real estate funds. The whole Berlin team in Catella Real Estate AG, consisting of 18 employees, has moved to CRIM to focus fully on further developing the residential fund management offering. Xavier Jongen and Michael Keune will be managing directors of CRIM. Catella Real Estate AG will continue managing the back office for all residential funds managed by CRIM.  For more information, please contact: Michael Keune Xavier JongenManaging director of CRIM Managing director of CRIM+49 (0)152 388 48 391 +49 (0) 891 891 66    Catella is a leading specialist in property advisory services, property investments, fund management and banking, with operations in 13 European countries. The group has sales of approximately SEK 2 billion and manages assets of approximately SEK 150 billion. Catella is listed on Nasdaq Stockholm in the Mid Cap segment. Read more at .

Conference call regarding Elekta’s Q2 report for 2017/18

STOCKHOLM, November 17, 2017 – Elekta (EKTA-B.ST) will publish its Q2 report for 2017/18 on November 30, as per: · The report will be published at 07:30 CET. · Elekta will host a telephone conference starting at 10:00 CET with Richard Hausmann, President and CEO, and Gustaf Salford, CFO. To take part in the conference call, please dial in about five minutes in advance. · UK dial-in number: +44 (0) 203 008 9808 · US dial-in number: +1 855 753 2237 · Swedish dial-in number: +46 (0) 8 566 426 91  The telephone conference will also be broadcasted live online, through the following link (however, in order to ask questions it is necessary to call in): # # # For further information, please contact:Johan Andersson, Director Investor Relations, Elekta AB.Tel: +46 702 100 451, e-mail: Time zone: CET: Central European Time Tobias Bülow, Director Financial Communications, Elekta ABTel: +46 722 215 017, e-mail: Time zone: CET: Central European Time About ElektaElekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm.

Dustin publishes Annual Report and Corporate Responsibility Report for 2016/17

Dustin’s full Annual Report and Corporate Responsibility Report for 2016/17 is now available in both English and Swedish at the company website, Dustin’s Annual General Meeting will be held on Wednesday, December 13, 2017 at 2:00 p.m. at the Playhouse Teater, Drottninggatan 71A in Stockholm, Sweden. Registration will begin from 1:00 p.m. For further information, please contact:   Fredrik Sätterström, Head of Investor Relations, +46 705 10 10 22 Contact person: Eva Ernfors, Head of Information, +46 702 58 62 94 This information is information that Dustin Group AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 11:00 CET on November 17, 2017. About Dustin Dustin is one of the leading Nordic resellers of IT products with associated services to companies, the public sector and private individuals. With its core business in e-commerce, Dustin functions as a bridge between the manufacturer’s wide-ranging offerings and customer requirements, in which Dustin’s employees support customers in finding the appropriate solution for them. Dustin is a one-stop-shop that offers some 250,000 products with associated services, features and solutions. Operations are conducted in Sweden, Denmark, Norway and Finland. The company has approximately 1 000 employees. Sales during the 2016/17 financial year amounted to approximately SEK 9.3 billion. About 90 per cent of Dustin’s income derives from the corporate market with a focus on small and medium-sized companies. Dustin Group has been listed on Nasdaq Stockholm since 2015 and has its head office in Nacka, Stockholm.

Eivind Roald to leave SAS

Eivind Roald joined SAS in 2012 as EVP Sales and Marketing. In 2014, he assumed the role as Chief Commercial Officer, a position he held until July 2017. He was then appointed Head of SAS Growth Initiative leading our efforts to incorporate EuroBonus to drive new revenue streams and further enhance customer loyalty. “Eivind Roald has been instrumental in transforming SAS into the number one choice for Scandinavia´s frequent travelers and realizing our vision ‘To make Life easier for Scandinavia´s Frequent Travelers’. Eivind is a true traveler with clear customer focus, energy and an entrepreneurial mindset that have paved the way to the strong position where SAS stands today. I would personally like to thank Eivind for his dedication, commitment and contribution to SAS during the six years he has been part of SAS Group Management. I respect his decision to change focus and wish him the best of luck in his new role,” says CEO Rickard Gustafson. “I’m humble and proud to see the result of all the hard work we have accomplished during the last six years. We have changed the company and developed and strengthened the SAS brand. With more than 5.3 million EuroBonus members we have doubled the number of members and secured a stable, loyal and profitable customer group.  I would like to thank the team that I have worked with, and I wish SAS all the best in the future,” says Eivind Roald. Eivind Roald leaves SAS at the end of November 2017. The responsibility for SAS Growth Initiative, which is an important part of SAS’ growth plan, will for the time being be held by SAS CEO Rickard Gustafson.

Bittium Corporation announces its financial calendar for 2018

Stock exchange release Free for publication on November 17, 2017 at 1.00 pm (CET+1) Bittium Corporation announces its financial calendar for 2018 In 2018, Bittium Corporation will publish its half year and annual financial reports as follows: · Financial Statement Bulletin 2017: on February 22, 2018, at 8.00 am (CET+1) · Half Year Financial Report January – June 2018: on August 8, 2018, at 8.00 am (CET+1) Bittium Corporation observes a three week silent period prior to announcing its financial reports. In 2018 the silent periods are as follows: · February 1 - February 22, 2018 · July 18 – August 8, 2018 Bittium will release its annual report 2017 on March 21, 2018. The Annual General Meeting will be held in Oulu, Finland on April 11, 2018 at 1.00 pm (CET+1). Oulu, November 17, 2017Bittium Corporation Further information Karoliina FyrsténDirector, Corporate Communications and MarketingBittium CorporationTel. +358 40 344 2789 Distribution Nasdaq Helsinki OyMain media Bittium Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its 30 year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. From November 2016 onwards, Bittium offers its customers also healthcare technology products and services in biosignal measuring in the areas of cardiology, neurology, rehabilitation, occupational health and sports medicine. Net sales in 2016 was EUR 64.2 million and operating profit was EUR 2.5 million. Bittium is listed on Nasdaq Helsinki. .

Sale of shares in Instalco Intressenter AB (publ) to the CEO


Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release November 17, 2017, at 3:15 p.m. Nokian Tyres has received an announcement from BlackRock, Inc. on November 17, 2017, according to which BlackRock, Inc.'s indirect holding in Nokian Tyres shares fell below level of 5% of the share capital in Nokian Tyres plc, as a result of a share transactions concluded on November 16, 2017. The indirect shareholding of BlackRock, Inc. in Nokian Tyres has decreased to 6,759,159 shares, corresponding to 4.92% of Nokian Tyres’ shares and voting rights. The mutual funds managed by BlackRock, Inc. held on deal date a total of 7,356,479 Nokian Tyres’ shares representing 5.36% of company’s 137,201,374 shares and voting rights. Total positions of BlackRock, Inc. and its funds subject to the notification:  +----------------+----------+------------------+------+----------------------+| |% of |% of shares and |Total |Total number of shares|| |shares and|voting rights |of |and voting rights of || |voting |through financial |both |issuer || |rights |instruments (total|in % | || |(total |of B)  |(A+B) | || |of A)  | | | |+----------------+----------+------------------+------+----------------------+|Resulting |4.92% |0.43% |5.36% |137,201,374  ||situation on the| | | | ||date on | | | | ||which threshold | | | | ||was crossed or | | | | ||reached  | | | | |+----------------+----------+------------------+------+----------------------+|Positions of |5.04% |0.37% |5.41% | ||previous | | | | ||notification  | | | | |+----------------+----------+------------------+------+----------------------+ Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rights: +------------+-----------------+-----------------+---------------+---------------+|Class/type |Number of shares |Number of shares |% of shares and|% of shares and||of shares |and voting rights|and voting rights|voting rights  |voting rights  ||ISIN code   | | | | |+------------+-----------------+-----------------+---------------+---------------+| |Direct (SMA 9:5) |Indirect |Direct (SMA |Indirect || | |(SMA 9:6 and |9:5) |(SMA 9:6 and || | |9:7)  | |9:7)  |+------------+-----------------+-----------------+---------------+---------------+|FI0009005318| |6,759,159  | |4.92% |+------------+-----------------+-----------------+---------------+---------------+|SUBTOTAL A  | |6,759,159  | |4.92% |+------------+-----------------+-----------------+---------------+---------------+ B: Financial instruments according to SMA 9:6a:  +-----------+----------+----------+-----------+---------+---------------+|Type of |Expiration|Exercise/ |Physical or|Number of|% of shares and||financial |date  |Conversion|cash |shares |voting rights  ||instrument | |Period  |settlement |and | || | | | |voting | || | | | |rights  | |+-----------+----------+----------+-----------+---------+---------------+|Securities |N/A  |N/A  |Physical  |534,238  |0.38%  ||Lent | | | | | |+-----------+----------+----------+-----------+---------+---------------+|CFD |N/A  |N/A  |Cash |63,082  |0.04%  |+-----------+----------+----------+-----------+---------+---------------+|SUBTOTAL B | | | |597,320  |0.43%  |+-----------+----------+----------+-----------+---------+---------------+ Nokian Tyres plc Antti-Jussi TähtinenVice President, Marketing and Communications Distribution: Nasdaq Helsinki Oy, media and

Leading Edge Materials Intersects Thickest Interval of Lithium Mineralization at Bergby, Sweden

Vancouver, Canada – Leading Edge Materials Corp. (“Leading Edge Materials”) or (the “Company”) (TSXV: LEM) (OTCQB: LEMIF) is pleased to announce results from the first five holes drilled as part of the second program of drilling completed at the Company’s 100% owned Bergby lithium project in Sweden.  Results from infill and step out holes have included the thickest mineralized interval intersected to date of 19.5m @ 1.12% Li2O (lithium oxide) in hole BBY17020.    Key Results: · BBY17019 intersected 12.6m @ 0.83% Li2O, from 21.1m depth · BBY17020 intersected 19.5m @ 1.12% Li2O, 184ppm Ta2O5 (tantalum oxide), from 13.6m depth · BBY17021 intersected 1.0m @ 0.96% Li2O, from 15.4m depth · BBY17023 intersected 8.2m @ 0.14% Li2O from 57.1m depth · BBY17024 intersected 8.1m @ 0.23% Li2O, from 56.1m depth Holes were drilled in the southern area of the prospect to infill and test down dip from previous drilling.  Of particular note, hole BBY17020, the second most mineralized hole drilled at Bergby to date, was both thicker and higher grade than holes on adjacent 50m sections (which graded 6.40m @ 0.64% Li2O and 16.35m @ 1.00% Li2O).  Furthermore, lithium mineralization in hole BBY17021 was discovered in an intermediate volcanic unit, rather than the pegmatite which had been the subject of all previous exploration and assaying.  The drill program is now complete, with 15 holes drilled for a total of 991.0m.  Bergby has now been tested by a total of 33 drill holes to a maximum depth of 131.1m over an approximate 1500m strike length.  Drill hole locations and results are provided in Tables 1 and 2 and presented as Figure 1. The true thickness of mineralized intervals is interpreted to be approximately 90% of the sampled thickness.  Blair Way, President and CEO, stated “Our exploration at Bergby has continued to deliver very promising results, and a high grade and thickness interval like 19.5m 1.12% Li2O at very shallow depth provides us with a lot of optimism.  While Bergby remains an early stage discovery, we are now preparing for metallurgical testwork to move the project to the next stage.  We look forward to sharing the next round of drill results from this second phase program as they become available.”  Bergby lies in central Sweden, 25km north of the town of Gävle, secured by three exploration licenses that cover a total of 1,903 Ha.  The site is close to infrastructure, with major roads, rail and power supply passing immediately adjacent to the claim boundaries. The potential for low cost and rapid development is significantly enhanced by the presence of a deep-water port only 5km from the site. On behalf of the Board, "Blair Way"                                                                                                                                        Blair Way, President & CEO The qualified person for the Company's exploration projects, Mark Saxon, Director of Leading Edge Materials, a Fellow of the Australasian Institute of Mining and Metallurgy has reviewed and verified the contents of this release. The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accept responsibility for the adequacy or accuracy of this news release. This is information that Leading Edge Materials Corp. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 17th November, 2017 at 0530 Vancouver time. Forward-Looking Information. This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include but are not limited to, the Company’s expectations regarding the lithium ion battery market; the successful completion of the drill program at Bergby; graphite production at Woxna, the Company’s preliminary economic assessment on Woxna is no longer current or valid as a result of the filing of a new NI 43-101 Technical Report effective March 24, 2015, and the Company has no plans to complete a new preliminary economic assessment, a pre-feasibility or feasibility study on the project, as such there is an increased risk of technical and economic failure for the Woxna graphite project; unexpected geological conditions; exploration activities to advance other critical material projects of the Company for energy storage markets, delays in obtaining or failure to obtain necessary permits and approvals from government authorities.  Although such statements are based on management's reasonable assumptions, there are risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Vattenfall invests in Ringhals upgrade

The investment will enable Ringhals to supply electricity into the 2040s. The decision to provide independent core cooling at Forsmark nuclear power plant was made last year. "This is a very positive decision, and it means that Ringhals will continue to supply climate-smart electricity for a long time to come. The investment comes at a time when essential measures are being taken to increase efficiency in order to meet the tough competition on the electricity market," says Torbjörn Wahlborg, Head of Vattenfall Generation and Chairman of the Board of Ringhals AB. The safety upgrade is a requirement set by the Swedish Radiation Safety Authority to enable operations to continue beyond 2020. “With the decision to upgrade Ringhals 3 and 4 with independent core cooling, we are adding a further safety system to plants that are already safe, and we can now plan for continued operation for the coming decades," says Wahlborg. Ringhals Board of Directors has also decided to extend the operation for Ringhals reactor one and two by up to six months. The timing of closure of the reactors is therefore postponed from June to December at the latest, 2020 (reactor 1) and 2019 (reactor 2). There will be no further extension. "By extending the operating period by up to six months, we can utilize the nuclear fuel we have already bought for fossil-free electricity generation instead of putting it straight into the planned final repository. The extension is profitable for Ringhals, for Swedish electricity generation and for the climate," says Björn Linde, CEO of Ringhals and Forsmark nuclear power plants. For further information, please contact:Vattenfall’s Press Office, telephone: +46 8 739 50 10, e-mail:

Kährs launches B2B e-commerce service

Through Kährs Direct, customers can see their assortment with customer-unique prices and delivery times. They can also request quotations, order floors and accessories, and easily get an overview of their relationship with Kährs – from quotation to order and delivery. "B2B flooring customers are a priority target group for Kährs, and our e-commerce service Kährs Direct is part of the group's general digitalisation journey. The ambition of the service is to improve the customer experience and increase transparency while simplifying workflows for both the customer and ourselves. Altogether, this will lead to increased loyalty, a strengthened position as a leading premium partner and more internal time for customer relations," says Christer Persson, President and CEO of Kährs Group. Kährs Direct is Kährs' second digital initiative in a short period of time. Earlier this year, a digital work platform for architects and project managers was launched. For further information, please contact:Helén Johansson, Corporate Communication, tel: +46 70 364 60 30 About Kährs Group Kährs Group is a Europe-leading flooring manufacturer in hardwood and resilient flooring with several strong brands in its product portfolio, including Kährs, Karelia and Upofloor. Kährs’ innovations have shaped the industry throughout history and the company is dedicated to providing private, commercial and public spaces with environmentally sound and long-lasting flooring solutions. Kährs Group, which delivers products to more than 70 countries, is the market leader in Sweden, Finland and Russia and holds a strong position in other key markets, such as Norway, the UK and Germany. The Group has approximately 1,700 employees and annual sales of more than SEK 3 billion.

Bayn Europe signed a strategic framework agreement entering China sugar reduction market

“It is important to maintain the margin and profit when the added sugar is replaced in the processed food and indulgence,” explains Lucy Dahlgren, CEO of Bayn Europe. “We are happy to have signed an agreement with a company that stands outside the traditional food value system, and that want to focus on enabling healthier lifestyles through sugar reduction initiatives. Kong Wua will be a valuable partner as we focus on expanding our business on the Chinese market.” The agreement between Bayn Europe and Kong Wua Group was undersigned 17thNov during the ceremony on “Belt and Road Innovative Cooperation Forum” at the China Hi-tec Fair, taking place on 16 - 21 Nov 2017 in Shenzhen China. "We have followed Bayn Europe and their commitment to sugar reduction during the past 3 years. In China, the economic growth has led to a change in lifestyle for many people. Recent overconsumption of sugar has caused an increase in social problems such as diabetes and child obesity. At Kong Wua, we see great value in investment opportunities that can help tackle these social problems, and contribute to positive change and healthier habits." says Qiaozhen Zhang, the president of Kong Wua Investment Group. "We are very happy that Bayn Europe, with their sugar reduction know-how and technical capabilities, have made the decision to enter the Chinese market.” About Bayn Europe  Bayn Europe is an independent formulation developer of cutting edge and healthy sugar reduction solutions for the food and beverage industry. Bayn’s total solutions focus on taste, texture and cost-in-use. Bayn’s product portfolio contains ingredients and sugar replacers for food and beverage applications. Bayn’s business model is based on solid networks of scientific research, market channel partnerships and contracted manufacturers. Bayn Europe was founded in 2009 in Stockholm, Sweden, and is listed at Nasdaq Stockholm, First North, since 2014. Mangold Fondkommission AB is Bayn’s Certified Adviser. Telephone +46-8-5030 1550. For more information, please contact Lucy Dahlgren, Managing Director Bayn Europe AB, e-mail  About Kong Wah Group The Kong Wah Group of Shenzhen was established in April 1996 with the Kong Wah Group of Hong Kong as a majority owner. The available funds at the time of registration were 150 million RMB. The group has a tradition of steady growth and pursuing of profitable projects. It strives for a modern business culture and its core values are honesty, trust and pragmatism. Today Kong Wah Group owns three high-technology parks, two ecology parks and over 200 000 square meters off first class office buildings spread all over the China. The group also holds investments in the industries of capital management, medical wine and amber jewelry. In total the Kong Wah Group controls 11 subsidiaries, found both locally and abroad. The Kong Wah Group is a people oriented and achievement driven organization and always chooses its projects with the utmost care. The organization acts with its shareholders and their return in mind - at the same time it strives to contribute to a more stable society. With its available funds, modern business management, and broad project competence The Kong Wah Group has become a well-known and respected entity in China. For more information: Denna information är sådan information som Bayn Europe AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 17 november 2017 kl. 15.30 CET

Eniro AB (publ) publishes a prospectus supplement

Eniro AB (publ) (”Eniro”) has prepared a supplement to the prospectus regarding the offerings to holders of preference shares and convertibles and the admission to trading of new Class A ordinary shares, which was approved and registered by the Swedish Financial Supervisory Authority on 8 June 2017. The prospectus supplement forms part of the prospectus and must be read together with the prospectus as well as the supplements to the prospectus that were approved and registered by the Swedish Financial Supervisory Authority on 2 August 2017, 22 August 2017 and 26 September 2017, respectively. The prospectus supplement has been prepared due to the publication of Eniro’s interim report for the period January–September 2017 on 25 October 2017. The prospectus supplement was approved and registered by the Swedish Financial Supervisory Authority today on 17 November 2017 and is available on Eniro’s website as well as on Pareto Securities’ website Pareto Securities is Sole Manager and Gernandt & Danielsson Advokatbyrå is legal advisor to Eniro in relation to the Exchange Offers. Roschier Advokatbyrå is legal advisor to Pareto Securities. For more information, please contact:  Björn Björnsson, Chairman of the board of directors, tel +46 70-399 80 16 Örjan Frid, President and managing director, tel +46 70-561 16 15 This information is information that Eniro AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 15.30 CET on 17 November 2017. Eniro is a leading search company for individuals and businesses in the Nordic region. Eniro Group has approximately 1,700 employees. The company is listed on Nasdaq Stockholm [ENRO], with approximately 14,000 shareholders at present and is headquartered in Kista, Stockholm. More on Eniro at,, This press release is available in Swedish at Important information                                                                        This press release does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares, subscription rights or other securities in Eniro. This press release has not been approved by any regulatory authority and is not a prospectus. In certain jurisdictions, the publication or distribution of this press release may be subject to restrictions according to law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and abide by such restrictions. This press release is not directed to persons located in the United States (including its territories and possessions, any state of the United States and the District of Columbia), Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or in any other country where the offer or sale of the subscription rights, paid subscribed shares new shares is not permitted. This press release may not be announced, published or distributed, directly or indirectly, in or into the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, other offer documentation, registrations or other actions in addition to what follows from Swedish law. The information in this press release may not be forwarded, reproduced or disclosed in such a manner that would contravene such restrictions or would require such additional prospectuses, other offer documentation, registrations or other actions. Failure to comply with this instruction may result in a violation of the United States Securities Act of 1933, as amended (the “Securities Act”) or laws applicable in other jurisdictions. No subscription rights, paid subscribed shares or new shares have been or will be registered under the Securities Act, or with any other securities regulatory authority of any state or other jurisdiction of the United States and no subscription rights, paid subscribed shares or new shares may be offered, sold, resold, transferred, delivered or distributed, directly or indirectly, into or within the United States or on the account of such persons other than pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act, and in compliance with any applicable securities laws of any state or jurisdiction of the United States. No public offering of subscription rights, paid subscribed shares or new shares is made in the United States. There is no intention to register any securities referred to herein in the United States or to make a public offering in the United States. This press release contains forward-looking statements which reflect Eniro’s current view on future events and financial and operational development. Words such as “intend”, “will”, “expect”, “anticipate”, “may”, “plan”, “estimate” and other expressions than historical facts that imply indications or predictions of future development or trends, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. The information, opinions and forward-looking statements in this press release speak only as of its date and are subject to change without notice.

Strategic Spin-Off

OSLO, NORWAY - (20 November 2017) – The Board and the Management of NattoPharma ASA have decided to spin-off the pharma business into the new company PharmaCo. NattoPharma ASA will continue as an operating entity, focused on its cash-generating supplement business. “We are very happy to finalize the spin-off of the pharma company and believe in a success for PharmaCo, based on the strong data accumulated over years of investments in research and clinical studies,” says Chairman Frode Bohan. “Various investors seek different types of investment and risk profiles. With two separate entities, the underlying value of the company will become more visible and thus create more shareholder value”, says Bohan. The supplement business will continue to grow while generating positive cash flow, and in the long term will have the potential to provide attractive dividends. PharmaCo, with its foundation of research, patents and intellectual property, and targeted therapeutic indications, will be attractive among investors in the pharma space. “Sales of our supplement business continue to reach new, and record, levels, and the pharma business is progressing into a very exciting stage. The timing of the spin-off has been carefully planned”, says CEO Daniel H. Rosenbaum. “I’m confident that the spin-off will enable greater focus across the entire organization, so we can continue to build the global leadership within vitamin K2 and MenaQ7. Further, we believe it’s time to add more critical mass to our dietary supplement business by focusing additional resources on expanding our product portfolio with new, scientifically validated ingredients.  An expanded product offering also allows us to take advantage of our existing global sales and customer technical support organizations”, says Rosenbaum. BACKGROUND NattoPharma’s main strategy is to build a global supplement business on the basis of vitamin K2 and other attractive ingredients. NattoPharma has over many years invested heavily in research and science in vitamin K2. Backed by the sales and marketing team in NattoPharma, these investments have been crucial to differentiate NattoPharma’s own vitamin K2 brand, MenaQ7. Today MenaQ7 is the world leading vitamin K2 supplement brand, and consumer demand continues to show robust growth. In the next years NattoPharma sees a great potential in focusing more on working with new and existing customers to capitalize on this increasing awareness and growing consumer demand for vitamin K2, and specifically MenaQ7. NattoPharma is the only player that have a full K2-product offering, including soy, natural soy-free, full spectrum and synthetic. With excellent market access and customer technical support across multiple geographies, the company sees additional opportunities to complement its current vitamin K2 brand strategy by adding new clinically-substantiated ingredients to its product family. The compelling clinical data obtained over the years along with ongoing research has created a strong basis for a focused pharmaceutical path. To pursue the therapeutic potential within the K2 pharmaceutical area, the Board has decided to establish a separate legal entity within which to organize this business. All patents, know-how and other pharmaceutical related assets will be transferred to a new, yet to be named, entity (to be referenced as “PharmaCo” for this announcement). This is already in progress and the spin-off of PharmaCo, including a rights issue of approx. NOKM 9, is planned to be finalized within the year end 2017. “PHARMACO” A comparable drug development process typically requires 5 - 10 years prior to commercialization and can involve costs in excess of USD 100-200 million. However, due to the fact that NattoPharma has over many years invested heavily in research and science in vitamin K2, the estimation for the first indication, according to an external CRO company, is that the product can be on the market within 4-6 years and to the estimated costs of USD 30-50 million. There will potentially also be major synergies related to both timelines and costs for additional indications. A successful process can create value of many multiples of this expenditure, depending, of course, on the target indications and effectiveness of results. Progressing a pharma project will require substantial funding over a prolonged period, and while providing for substantial upside, it also involves high risk. The risk profile and business model for a pharma company differs significantly compared to the model for a supplement company. In recognition of these distinctions, the Board of NattoPharma believes that the preferred path forward for both current and potential future shareholders is to de-risk the K2 supplement business by spinning-off the pharma company, while at the same time creating the opportunity for today’s shareholders to participate directly in PharmaCo as investors, and thereby participate in the potential upside this business case has to offer. PharmaCo’s business plan will be to capitalize on compelling vitamin K2 data and intellectual property with application in specific therapeutic areas. Several indications for pharma development have been identified. The initial priority is to pursue the promising indication areas through phase I and phase II, and to then expand the breadth of applications with additional submissions. Concurrently, discussions regarding commercial partnership and co-development will continue with larger pharmaceutical companies, and the board believes that the timing for the spin-off is will further enable these discussions. The plan is to seek operational funding in 2018 while seeking to establish partnership roles with one or more larger pharma companies. The funding amount for 2018 and beyond will be impacted by the outcome of discussions with the potential pharma partners. One typical model under evaluation is for the larger pharmaceutical partner to finance a significant portion of the investments in new studies and regulatory work, while PharmaCo will focus on project management, intellectual property development and initiation of new indication areas. Cash flow for the licensing entity will typically come from a combination of a sign on fee, milestone payments and royalty when (and if) the drug is introduced to the market place. THE TRANSACTION PharmaCo will be established as a 100% owned legal entity of NattoPharma ASA. All rights related to the pharmaceutical business, currently controlled by NattoPharma ASA, will be transferred to PharmaCo. The valuation of this business is expected to be in the range of NOKM 50 to 70. A part of the value related to the business that will be transferred, will be used as in-kind contribution of equity and the remaining will be sold to the new entity. This will be financed through a vendor loan from NattoPharma on reasonable market terms. The Board in NattoPharma has initiated a process to identify candidates to the Board of Directors in the Pharma entity. The new board will consist of persons with a proven experience within the pharmaceutical business segment. This is expected to be completed within the next 4 to 6 weeks, and the company will have an interim Board of Directors in the period until this process is finalized. The new Board of Directors will then start immediately to put together an independent management team. Until a permanent management team is in place, expected to happen within 3-6 months, the current CEO, CFO and CMO in NattoPharma will work hand in hand with the new Board. PharmaCo will be established with NOK 30.000 in paid in share capital in November 2017, as a limited liability company incorporate under the laws of Norway (AS). In addition, transfer of the pharma business valued at NOKM 50 to 70, distributed partly as in-kind contribution of equity and an acquisition of a business, will take place in November 2017. To create an independent company and secure the initial working capital, a private placement will be facilitated in PharmaCo. All existing NattoPharma ASA shareholders as of 28th of November 2017 will be invited to subscribe new shares in PharmaCo. The market valuation of PharmaCo after the initial in-kind contribution from NattoPharma is expected to be approx. NOKM 8. The placement will be done for an amount of approx. NOKM 9. NattoPharma plan to own 40-49% of PharmaCo, while remaining 51-60% will be owned by existing NattoPharma ASA shareholders. The ownership distribution will depend on the subscribed amount, but NattoPharma plan to reduce the ownership under 50% in any circumstance. The subscription period is planned to start 29th of November and end at 12th of December 2017. The new share capital should be paid in and registered before year end 2017. Final dates to be released in a separate message later. A separate listing within 12 months on a Norwegian, Swedish or other international stock exchange will be evaluated by the new Board in PharmaCo. NATTOPHARMA GOING FORWARD NattoPharma and PharmaCo will enter into a licensing agreement, where NattoPharma exclusively will have access to all relevant know-how and patents, crucial to operate the K2 supplement business. NattoPharma will pay a yearly license fee to PharmaCo for the rights to use the transferred patents in the supplement business. This will include the right to use any future patent granted to PharmaCo for new claims or other intellectual property that PharmaCo obtain in the initial license period. After completing the series of transactions, NattoPharma will focus exclusively on building a strong sales and marketing company, while still retaining, with limited risk, the potential benefits of the pharmaceutical upside. Transferring all future investments in science and pharma driven projects will immediately reduce the operating cost base for NattoPharma. With strong growth in the supplement business, combined with significant reduction in operating costs, 2018 should be the first full year with operating profit for NattoPharma ASA, and a foundation in place for a future with a continuous dividend stream.

Cooperation with The Barton Group for Engebø garnet sales and project development

The Barton Group agreementSince 2011, Nordic Mining and Barton (together “the Parties”) have had a Memorandum of Understanding (“MoU”) with the intention to establish a long-term cooperation with regards to development, production, sales, marketing and distribution of garnet products from Engebø. Barton has analysed and confirmed the high-quality of the garnet products which have been produced in the Engebø prefeasibility testwork.Today, the Parties have entered into a Heads of Agreement (”HoA”) confirming the cooperation, which will be further developed based on the following main principles:  · Offtake agreement for North-AmericaNordic Mining and Barton have agreed the basic principles of an offtake agreement for the exclusive distribution by Barton of Engebø garnet to the North American markets. The garnet will be sold and distributed under Barton’s brand name for high-quality products.      Barton is a substantial producer and distributor in North America with 23 warehouses and an experienced marketing and technology organization supporting customers all over the continent.       · Joint venture agreement for other marketsNordic Mining and Barton intend to establish a jointly owned company (“Newco”) for sale and distribution of garnet from Engebø to markets outside of North America. The terms and conditions for the operation and the Parties’ cooperation will be further negotiated.      The high quality of the Engebø garnet and cost-efficient logistics, combined with Barton’s comprehensive marketing and technology experience, are expected to build competitive strength.      · Financing of pre-construction project developmentBarton intends to participate in the pre-construction financing of the Engebø project. The financing will be on the same terms as offered to other investors if Nordic Mining should decide to arrange an equity issue related to funding of pre-construction activities for the Engebø project.      · Construction financingBarton intends to participate in the construction financing of the Engebø project as an industrial anchor investor. The form and amount of Barton’s contribution will be further negotiated and evaluated as part of the total solution for project financing. Comments from Nordic Mining and Barton Chairman of the Board of Nordic Mining, Tarmo Tuominen comments:“We are very pleased with the agreement, which confirms the relation with Barton and the parties’ intention to play a leading role together in the international garnet industry. Barton’s achievements and leading position in the development of waterjet cutting is impressive, and we look forward to the successful building of a strong and mutually beneficial partnership.”   CEO Nordic Mining, Ivar S. Fossum comments: “Barton’s confirmation of the quality of the Engebø garnet is the best assurance we could get. The hard-rock garnet quality combined with Barton’s experience and competencies forms a solid basis for our collaboration. We look forward to moving forward together with Barton as the world’s leading garnet technology company.” Chairman and CEO of The Barton Group, Charles Bracken, comments:  “Barton is very pleased to be working with Nordic Mining to develop this world-class resource. Nordic Mining and Barton’s core values are aligned in our commitment to quality, safety, environment, innovation and integrity. We look forward to leveraging the strengths of both companies to create long-term value for all stakeholders.” Information about The Barton Group ( Barton is a family-owned company founded in 1878 that has produced the world’s highest-quality garnet abrasives for more than six generations. The company’s initial operation included mining and milling garnet for the sandpaper industry. Because of its ever-sharp crystalline structure, Barton garnet quickly became the world standard for sandpaper applications. Over the years, Barton has continued to develop new products, markets and applications – including blasting abrasives, waterjet abrasives and waterjet parts. Barton has a strong commitment to quality, performance and service to communities and customers. Today Barton produces garnet abrasive products for many diverse applications such as waterjet cutting, blast media, bonded and coated abrasives and specialty lapping and grinding medias. Barton owns and operates mining and milling operations in the Adirondack Mountains of upstate New York. The facility operates year-round to meet the demand for quality, high-performance garnet abrasives. For questions, please contact CEO Ivar S. Fossum, telephone +47-930 96 850.Oslo, 20 November 2017Nordic Mining ASA About Nordic Mining ASA ( Mining ASA (“Nordic Mining” or “the Company”) is a resource company with a focus on high-end industrial minerals and metals in Norway and internationally. The Company’s project portfolio is of high international standard and holds significant economic potential. Nordic Mining is undertaking a large-scale project development at Engebø on the west coast of Norway where the Company has rights and permits to a substantial eclogite deposit with rutile and garnet. Permits for the project have been granted by the Norwegian government, and a prefeasibility study was completed in October 2017. Nordic Mining’s associated company Keliber in Finland is in the process of completing its definitive feasibility study and preparing for production of lithium carbonate. Nordic Mining has rights for exploration and production of high-purity quartz in Kvinnherad in Norway. Further, the Company holds exploration rights at Reinfjord in northern Norway where a prospective area of sulphide mineralisation has been discovered. Nordic Mining is also exploring opportunities related to seabed mineral resources.Nordic Mining is listed on Oslo Axess with ticker symbol “NOM”.

Nomination Committee appointed for the Annual General Meeting 2018

In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of four members. The chairman of the Board of Directors shall contact the three largest shareholders of the Company, in terms of voting power, pursuant to Euroclear Sweden AB’s print out of the share register on 31 August. Each of the three largest shareholders shall be offered the opportunity to, within reasonable time, appoint a member who, together with the chairman of the Board, will constitute the Nomination Committee. The Nomination Committee for the 2018 AGM in Bactiguard Holding AB (publ) consists of the following members: Stanley Brodén, Chairman of the Board of DirectorsJan Lombach, appointed by KK Invest ABThomas von Koch, appointed by Bactiguard B.V.Christian Brunlid, appointed by Handelsbanken Fonder AB The Nomination Committee will make proposals to the AGM 2018 concerning the election of a Chairman for the AGM, the Chairman and other members of the Board of Directors, as well as auditors. The Nomination Committee will also make proposals regarding remuneration to the Board of Directors, including any separate remuneration for committee work, as well as remuneration to the auditors. Further, the Nomination Committee will make a proposal regarding principles for forming the Nomination Committee for the AGM in 2019. Shareholders who wish to make proposals to the Nomination Committee can do so by writing to the Nomination Committee under the following address: Nomination CommitteeBactiguard Holding AB (publ)Box 15146 21 Tullinge Proposals can also be sent by email to the following address: In order for the Nomination Committee to be able to address proposals in a constructive manner, they should have been received by January 19, 2017. The proposals of the Nomination Committee will be presented in the invitation to the AGM and at the company’s website. For further information, please contact: Cecilia Edström, CFO, cell phone: +46 72 226 23 28

Interim Report Third Quarter 2017

Third quarter · In our previous second quarter report we noted the results should be considered against a strong comparative in the second quarter of 2016. The third quarter results should now however be considered against a weaker comparative in the third quarter of 2016. · Net sales increased by 6% to SEK 95.6 (90.0) million. Adjusted to fixed exchange rates, net sales increased by 9%. · Adjusted operating profit increased by 7% to SEK 28.8 (26.9) million. · Adjusted profit before tax increased by 24% to SEK 21.8 (17.6) million. · In September 2017, Diamorph AB (publ) redeemed all of its remaining SEK 450 million of outstanding bonds. The transaction required the payment of an early redemption premium of 3% (SEK 13.5 million) to bondholders. The bonds were redeemed using a combination of existing surplus cash accumulated within the Group as well as from proceeds drawn down through a new senior secured bank facility. · Operating profit (as reported under IFRS) increased by 8% to SEK 27.8 (25.8) million. · Profit before tax (as reported under IFRS) decreased by 64% to SEK 7.1 (19.7) million. First nine months   · Net sales increased by 1% to SEK 317.1 (313.0) million. Adjusted to fixed exchange rates, net sales increased by 1%. · Adjusted operating profit increased by 3% to SEK 108.1 (104.7) million. · Adjusted profit before tax increased by 9% to SEK 83.5 (76.8) million. · In February 2017, Diamorph AB (publ) acquired the final 10% of Diamorph Bearings AB and so today controls 100% of each of its subsidiaries. · Operating profit (as reported under IFRS) increased by 9% to SEK 110.2 (101.2) million. · Profit before tax (as reported under IFRS) decreased by 29% to SEK 82.8 (116.0) million. The full report is attached to this press release and is also available for download at For additional information, please contact:Gordon MacLeman, CEOTelephone: +44 161 955 2410 Mark Hutchison, CFOTelephone: +44 161 955 2409 The information was submitted for publication on November 20, 2017, at 08:00. Diamorph supplies advanced material solutions for especially demanding industrial applications. The Company is headquartered in Stockholm and has subsidiaries in the United Kingdom and the Czech Republic. Learn more at

Henrik Borelius has decided to leave his position as CEO after 17 years at Attendo

“During his 17 years at Attendo, Henrik Borelius has led the company through a unique transformation, from a company in crisis to become the leading care company in the Nordics. Under Henrik’s leadership Attendo has grown revenues more than 10 times to become the Nordic market leader with satisfied customers, high quality, satisfied employees and the industry’s best margins. Henrik combines strong analytical and strategic capabilities, business leadership close to the operations and a high level of energy. This has been invaluable in the role of CEO. The board and I would like to thank him for excellent work in developing Attendo and the care industry, and we wish him all the best as he moves on to new opportunities”, says Ulf Lundahl, chairman of Attendo. “It has been a pleasure and a privilege to lead Attendo during these years and to work with so many driven and talented colleagues. I am very proud of what we have achieved together to gain the trust to provide care to so many customers and payors across the Nordics. Attendo has a stable platform for the future with a strong culture based on our vision, empowering the individual”, says Henrik Borelius, CEO. “Attendo is stronger than ever, and with the competent and committed management team surrounding Henrik there is every opportunity for continued good performance. We have already started the process of finding a new CEO for Attendo”, says Ulf Lundahl. The board of directors has initiated the process of appointing a successor. Henrik Borelius will continue as CEO in Attendo during his termination period until May 2018 and will remain as a board member until the Annual General Meeting 2018. Attendo AB (publ) For further information, please contact: Andreas Koch, Communications and IR DirectorPhone: +46 705 09 77 61E-mail:  Attendo AB (publ) is required to disclose this information under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was provided by the above contact for publication on 20 November 2017 at 08.00 CET. _________________________________________________________ Attendo – the leading care and healthcare company in the Nordics Attendo is the leading private provider of publicly financed care and healthcare services in the Nordic region. The company was founded in 1985 and was first to provide outsourced care for older people in Sweden. In addition to care for older people, Attendo provides care for people with disabilities, individuals and families, and, in Finland, healthcare and dental care. Attendo has more than 20,000 employees and is locally anchored with over 600 operations in more than 200 municipalities in Sweden, Finland, Norway and Denmark.

MAG Interactive intends to list its shares on Nasdaq First North Premier

MAG Interactive AB (publ) (”MAG Interactive” or the ”Company”), a leading developer and publisher of casual mobile games, is today announcing its intention to proceed with an initial public offering of the Company’s shares on Nasdaq First North Premier (“the Offering”). The listing is, subject to market conditions, expected to occur before the end of the fourth quarter 2017. Didner & Gerge Fonder AB, Handelsbanken Fonder AB on behalf of managed funds, RAM ONE AB on behalf of managed funds, Chalex through Chalex i Göteborg AB and Swedbank Robur Fonder AB on behalf of managed funds (together the ”Cornerstone investors”), have committed to subscribe to a number of shares such that their joint investment amounts to SEK 230 million based on the IPO price (“Offering Price”), which amounts to SEK 44 per share, pending certain customary conditions. Daniel Hasselberg, CEO and co-founder of MAG Interactive: ”It has been an exhilarating journey since the launch of Ruzzle in 2012. We are fortunate to have some astonishing, ambitious, hard-working and driven people in this Company. Together we have come far, but we are nowhere near done. We are still at the beginning of our journey with the listing being an important milestone, and an important step for us as a company. In addition to diversifying the ownership structure, the listing will contribute to awareness about MAG Interactive, something we are convinced will be beneficial for our growth journey ahead“. Walter Masalin, Chairman of the Board of MAG Interactive: ”These are exciting times. It is with significant pride the board looks at what the Company has achieved. MAG Interactive has established a strong position within casual mobile games, and has proven to be able to expand its focus from the word game category to the broader and larger casual category, not least through the acquisition of FEO Media AB (”FEO Media”). With a clear strategy for continued profitable growth, we are excited to broaden the ownership base and offer the opportunity for an enlarged group of shareholders to follow us into the exciting future of the Company.” About MAG Interactive MAG Interactive is a leading developer and publisher of casual mobile games for a global audience. The Company’s game portfolio consists of ten[1] successful games, nine of which have been downloaded in excess of one million times. The tenth game Backpacker, was launched in October 2017 and has subsequently not reached one million downloads yet. Combined, the Company’s ten games have been downloaded in excess of 200 million, a milestone reached in conjunction with the acquisition of FEO Media in November 2017. MAG Interactive attracts a global audience with net sales spread out across the globe. As of 31 August 2017, the Company had 1.6 million Daily Active Users and 7.4 million Monthly Active Users playing MAG Interactive’s games. If FEO Media’s players for the corresponding period were to be included, Daily Active Users would increase to 3.2 million and Monthly Active Users would increase to 12.8 million. While the Company started out within the word game niche with the game Ruzzle, the current focus is the broader casual mobile gaming space. The current portfolio contains ten games, of which five are word games, one is a puzzle game and four are trivia games. Over the years, MAG Interactive has developed a scalable and repeatable game development process, based on a scientific approach to ensure quality and frequency of all productions. MAG Interactive’s games are distributed through virtual app stores allowing for global reach with minimum effort, of which the largest are Google Play and App Store, for operating systems Android and iOS respectively. Partly due to the high quality and rankings of its games, the Company enjoys strong relationships with distributors such as Apple and Google, which facilitates and improves the Company’s publishing and marketing activities. The Company recorded net sales of SEK 335 million and EBITDA of SEK 58 million during 2016/2017 on a pro forma basis[2]. Net sales has grown significantly since 2014/2015 at a CAGR of 48 per cent. Headquartered in Stockholm, MAG Interactive has been running current operations since 2011 and had 57 employees as of 31 August 2017. The acquisition of FEO Media adds some 50 additional employees. This information was released for publication at 08:00 CET on 20 November 2017. ---------------------------------------------------------------------- [1] Games that are published by MAG Interactive [2] MAG Interactive acquired FEO Media in November 2017, and therefore pro forma accounts have been established for the fiscal year 2016/2017

MMT starts offshore geophysical survey for AQUIND Interconnector

Image: MMT´s Survey and ROV vessel Franklin MMT will utilise two vessels: M/V Franklin for offshore works and M/V Seabeam for nearshore works. The vessels are equipped with latest state-of-the-art survey technology including multibeam echo sounders, side-scan sonars and sub-bottom profilers. AQUIND, MMT and their representatives maintain ongoing contact with UK and French fisheries, which may be affected by the survey, in order to mitigate any potential impact on their fishing activities. The survey results will inform AQUIND’s final route selection and support planning applications to the UK and French authorities. AQUIND and its advisors are liaising with relevant consent granting bodies in both countries to ensure that the survey scope complies with applicable standards. Stefan Eliasson, MMTs CEO, comments on the project: “We are delighted to have the opportunity to support the AQUIND Interconnector project work and look forward working with the Aquind Team to deliver a successful marine survey campaign along the proposed cable corridor. This shows that MMT can provide our customer with effective, high quality survey solutions meeting their high requirements.” Kirill Glukhovskoy, AQUIND Managing Director added: “MMT is one of the leading specialists in the marine surveying solutions with extended experience in working in the English Channel. We are looking forward to fruitful cooperation on the AQUIND cable survey in the coming months” Note to editors: AQUIND Interconnector is a proposed new subsea and underground High Voltage Direct Current power transmission link between the South Coast of England and Normandy in France. With the capacity of 2,000 MW, AQUIND Interconnector will improve security of supply, help foster greater renewable power integration and make the national grids more robust by supplying them with vital ancillary services. The project is fully private and is being developed without any government subsidies. Specialising in high resolution subsea surveys, MMT is the solution to your marine surveying needs. We collect, process and visualise the conditions of the seabed. We offer assured surveys in bathymetric, geophysical and geotechnical services, specialising in the oil & gas, hydrography and renewable energy & marine cable sectors. Our competence and services will supply you with the relevant information, designed to fit your planning processes of your offshore infrastructure projects.

Studsvik appoints new head of Fuel and Materials Technology business area

Joakim Lundström, aged 39 and holding an M.Sc. in Engineering Physics, has been appointed head of the Fuel and Materials Technology business area. Joakim Lundström is currently and will continue to be President of Studsvik Nuclear, which houses the Fuel and Materials Technology operations and nuclear facilities. He has long experience of the nuclear power industry and has worked in the Studsvik Group since 2002. Joakim Lundström will be a member of Studsvik's Executive Group Management and will take up his post on January 1, 2018. For further information, please contact: Michael Mononen, CEO Studsvik AB, +46 155 22 10 86 or +46 760 02 10 86. Facts about Studsvik Studsvik offers a range of advanced technical services to the global nuclear power industry. Studsvik’s business focus areas are fuel and materials technology, reactor analysis software and consultancy services within waste treatment technology, decommissioning, NORM and solutions for final disposal. The company has 70 years nuclear technology and radiological service experience. Studsvik has 700 employees in 7 countries and the company’s shares are listed on Nasdaq Stockholm. This information is information that Studsvik AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on November 20, 2017, at 08:45 AM (CEST).

Saab Awarded SANDF Mass Field Feeding System Contract

The contract will supply the SANDF with mobile containerised kitchens systems which consists of 24 x 50-man systems and 11 x 200-man systems. “Saab is committed to supporting world class capabilities for the SANDF. This contract represents our efforts in strengthening our partnerships with military veterans and small and medium-sized enterprises - in line with national imperatives in South Africa,” says Trevor Raman, President and CEO of Saab Grintek Defence. The 200-man system consists of a fully equipped Expandable Kitchen Unit, a Reefer Unit, for cold storage of rations, Utility Unit, to accommodate potable water, diesel and waste water and a Storage Unit. The 50-man system consists of a fully equipped expandable unit and bladders to handle the potable and waste water. The grillers, convection ovens and boiling pans are based on modern diesel fired technology, which forms part of the SANDF initiative reduce liquefied petroleum gas. The units are able to operate from the available power grid or as a stand-alone system with its own power generation mounted in the kitchen container unit. Saab has a proven record in supplying field facilities and camp sites for armed forces; completely packaged multi-function field facilities as well as shelter and portable modules for a wide range of operational applications. The project will be executed by Saab in Centurion, South Africa, over a period of approximately two years. For further information, please contact:Saab Press Centre,+46 (0)734 180 us on twitter: @saab   Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.

Stora Enso will bring renewable materials to Seefeld Nordic World Ski Championships 2019

Throughout the event, Stora Enso wants to increase the participants’, viewers’ and visitors’ awareness of the benefits of sustainable products. Stora Enso’s products provide a climate-friendly alternative to many products made from fossil based materials, and have a smaller carbon footprint. During the World Ski Championships, a variety of products and solutions based on renewable raw materials will be show casted, such as wood for temporary buildings, carton board packaging, paper, effective waste management systems, and renewable materials for arenas. This marks the third time Stora Enso will be sponsoring the Nordic World Ski Championships, after being the Presenting Sponsor for the 2017 event in Lahti, Finland, and a main sponsor of the event in Falun, Sweden in 2015. This is a good opportunity for Stora Enso to be present close to its main markets. The group employs approximately 5 000 people in Central Europe. In Austria, the group operates sawmills and plants for wooden construction elements, CLT. “We are very happy to be sponsoring the FIS Nordic World Ski Championships for the third time,” commented Stora Enso CEO Karl-Henrik Sundström. “Sustainability is the core of our business in the bioeconomy. Our products substitute fossil based products, such as plastics. In Seefeld, our renewable materials and expertise will be combined in many special products and solutions. We will lead the way in promoting and supporting a sustainable event, by using renewable raw materials derived from wood and by maximising the recycling and reuse of products.” For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228 Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper on global markets. Our aim is to replace fossil-based materials by innovating and developing new products and services based on wood and other renewable materials. We employ some 25 000 people in more than 35 countries, and our sales in 2016 were EUR 9.8 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY).   STORA ENSO OYJ 

Toxicology and Safety Studies are Successfully Completed

Safety studies are a critical step in the development of a pharmaceutical. Redwood Pharma has now successfully completed these regarding RP101, which is a new candidate drug based on a well-known active substance and IntelliGel® - that will for the first time be used in an ophthalmological treatment, which will be administered directly onto the front of the eye. The completion of the studies confirms that RP101 and the IntelliGel platform do not result in any significant toxicology effects. This means for the development of RP101 and the IntelliGel platform that Redwood Pharma can: -       Seek an advisory meeting with the (Swedish) Medical Products Agency to finalize our working development plan. -       Finalize regulatory documentation needed for the clinical trial application. -       Intensify activities to find a new area of use (new products) that could benefit from IntelliGel. CEO Martin Vidaeus is quite positive to the developments, ”These safety data contribute to RP101s strength as a future therapy to treat dry eye disease and increases the opportunity for the use of IntelliGel together with other active substances. With these results in hand, we continue to be optimistic about the Company’s future commercial potential. The positive results minimize development and investment risks – at the same time the value of Redwood Pharma increases.” For more information:Martin Vidaeus, CEO Redwood Pharma AB (publ.)Tel: +46 (0) 70 232 29 29E-mail: This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, November 20, 2017.

Follicum applies for the start of a Phase II study at the German Medicines Agency

Preparations for the new clinical Phase IIa study with FOL-005 on scalp are progressing as planned, and we have now reached an important milestone in submitting the application to the authority and Ethics Committees in collaboration with the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and Bioskin, Hamburg, Germany. The notice regarding the application is expected to arrive around the turn of the year. Follicum plans to start the study in the first quarter 2018 with recruitment of patients both in Berlin and Hamburg. The goal of Follicum's new clinical study is to investigate the effect and response of the drug candidate FOL-005, on the scalp with injections. The planned study will include approximately 60 patients with gradual hair loss. Treatment will be performed on two surfaces of the scalp where different doses of FOL-005 or placebo will be administered. The company intends to complete and communicate the results of the study in 2018. CEO Jan Alenfall’s comments" Submission of the application for the new clinical study on scalp is another important milestone for Follicum. Our intention with the forthcoming study is to confirm the interesting results from the recently completed study, where we saw good effect and safety as well as a very high patient response.”  About Clinical Research Center for Hair and Skin Science (CRC), Berlin, GermanyThe Clinical Research Center for Hair and Skin Science ("CRC") is part of the skin clinic at the Charité University Hospital in Berlin. CRC conducts experimental research and offers specialist expertise in the field of skin and hair research. CRC has conducted a number of clinical studies in various hair indications and has a solid qualification area specializing in clinical phase I and II studies. About Bioskin, Hamburg, GermanyBioskin is a full-service CRO specializing in dermatology that provides services for clinical development of dermatologically oriented products, especially for both early phase/PoC and late phase studies. Bioskin has 25 years of experience in clinical studies in this area. Bioskin has previously conducted several clinical studies in various hair indications and has impressive qualifications. The head office is located in Hamburg and is privately owned. For further information, please contact:Jan Alenfall – CEO Follicum ABTelephone: +46 46 19 21 97Email: This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 20th November 2017.  About Follicum ABFollicum was founded in 2011 by two researchers in Lund, Anna Hultgårdh and Pontus Dunér, based on research around a human protein, osteopontin. Among other things, this protein is considered to be involved in the growth of bone tissue. Follicum has isolated a part of this protein and partially modified its amino acid sequence, which generated Follicum’s drug candidate FOL-005. In early studies, FOL-005 showed an ability to both stimulate and inhibit hair growth. During 2016/2017, the company conducted its first clinical phase I/IIa study. Follicum is based in Lund and was listed on AktieTorget in 2014.

Finland 100 celebrations further enliven the Christmas season in Helsinki

Photo:Jussi Hellsten This year the Christmas season in Helsinki promises to be more eventful than ever. In addition to all our traditional Christmas events, we will be celebrating the 100th anniversary of Finnish independence for two whole days – on 5 and 6 December 2017. The Christmas season in Helsinki stretches from the end of November all the way to the beginning of January, during which period the theme of “light” will entertain locals and visitors alike while livening up the city in many ways. The full programme can be found on the MyHelsinki  website. Christmas in Helsinki will be full of events and a wonderful atmosphere this year. Traditional Christmas events, such as the opening of the Christmas street, the Helsinki Christmas Market and the Lucia Parade, will be joined by many new happenings and experiences. For example, a family fun run will take place around Finlandia Hall on 2 December, while Christmas Paths will attract families to Vuosaari on 3 December and Seurasaari on 10 December. In the Esplanade Park, traditional Finnish Christmas food will meet flavours from around the world when the NUUR pop-up café and shop opens on the Espa Stage on 4 December. Meanwhile, visitors can enjoy a Christmas sauna at the Helsinki Christmas Market in Senate Square, and the Allas Sea Pool will be celebrating the season with lights and water on 2-26 December. Finland’s 100th birthday to be celebrated over two days This year Independence Day will be widely celebrated also in the nation’s capital as the Republic of Finland turns a hundred. The birthday celebrations in Helsinki will take the form of a two-day city festival, the programme for which is being created together with local residents, communities and businesses. A new tradition is also being created for Independence Day: a fun and joyful Independence Day Eve. “It’s great that new ways of celebrating are being created alongside our old traditions and that Finland’s centenary is inspiring locals to do things together. Many of the nation’s most important Independence Day traditions take place in the capital, so Helsinki plays an important role in leading the national celebrations,” says Mayor Jan Vapaavuori. The official opening ceremony of the Independence Day celebrations will take place at the Market Square in Helsinki at 6pm on Tuesday 5 December. The birthday celebrations in Helsinki will then end together with the Finland 100 centenary year at 10pm on Wednesday 6 December with an impressive fireworks display over the South Harbour. Hundreds of events will take place between these two special occasions, inviting locals and visitors to celebrate the nation’s birthday together – both indoors and out, at home and in the city. Exciting ice hockey will be placed at the Helsinki Ice Challenge in Kaisaniemi, the city’s museums and open-air skating rinks will be open, family events will be held in many public libraries, Art goes Kapakka will bring culture to bars and restaurants, choirs will sing throughout the city centre, and many community centres will organise their own local celebrations. Celebrating Christmas and the New Year with the theme of “light” This year locals and visitors will be able to enjoy the light in Helsinki throughout the entire holiday season, as the main theme from the opening of the Christmas street to the beginning of January will be “light”. The traditional Christmas lights around the Esplanade, Aleksanterinkatu and Senate Square will be further enhanced this year. Special lighting will create a unique atmosphere in the city to mark Finland’s birthday from 5 to 6 December, when major buildings including City Hall, the Presidential Palace, Helsinki Cathedral, the Government Palace, the main building of the University of Helsinki, Finlandia Hall, the Olympic Stadium Tower and the Helsinki Central Library Oodi will be illuminated in blue and white lights. Töölönlahti Park will also feature an interactive light installation entitled “Generation.Now” throughout the Christmas season. Locals will also be challenged to bring light to the darkest time of the year as part of the Lux Helsinki light festival. Locals can participate in the “Light Challenge” by sharing a photo or video of their own light installation on Instagram or Twitter using the hashtag #valohaaste. Further information: Jenni Pöyry, Press OfficerHelsinki, tel. +358 40 709 2913 See the complete programme for the Christmas season and the Independence Day celebrations in Helsinki:  Note to media representatives: A service point for the media will be set up in the main lobby of City Hall throughout the Independence Day events. The service point will be open 3pm-8pm on Tuesday 5 December and 3pm-12midnight on Wednesday 6 December. Accreditation is not required, but kindly show your media ID when visiting the service point. Special traffic arrangements will be in made in the city centre during the Independence Day celebrations on 5-6 December. Information about traffic arrangements: Roy Koto, Information OfficerCity Environment, tel. +358 9 310 38 644 **** Helsinki Marketing is a marketing company owned by the City of Helsinki. Helsinki Marketing is responsible for Helsinki’s operative city marketing and business partnerships. Helsinki Marketing works in close cooperation with local residents, visitors, decision-makers and experts.

Ethiopian Church in Stockholm 'Highly Commended' at the World Architecture Festival

World Architecture Festival is the world's largest international architectural event where the premier buildings of the year around the world are awarded. This year the festival took place in November in Berlin, Germany. The jury appreciated the strong sculptural feature of the church, it's connection to history across the borders and the way it offered a civic space to a community larger than the parish. - Being awarded in an international context like the World Architecture Festival is especially rewarding as it proves that our projects are of international standards, says Rahel Belatchew, Principal Architect, CEO and Founder, Belatchew Arkitekter. - This project also shows how a building intended for a congregation could simultaneously become a meeting place for a neighborhood. Bridges are built over cultures for better social cohesion and buildings in the city are optimally utilized. Both these aspects play a crucial role for the sustainable cities of the future, Rahel Belatchew concludes.   ABOUT THE ETHIOPIAN CHURCH IN STOCKHOLM This project is about creating a place for a community and bringing together an ancient tradition with modern needs in another part of the world. The building is composed of coloured concrete that takes up the colour of the red African soil and the weight and materiality from the unique rock hewn churches of Lalibela in northern Ethiopia. The feeling of weight being conveyed by the outwardly inclined walls. On the inside, the Scandinavian tradition of wood is visible through large timber frames and panels. The main feature of the church is its large, round church hall with a central dome. The deliberately introvert volume takes in daylight from above avoiding openings in the façade. The lack of openings in the facade enables the visitor to start an inner spiritual journey without distraction from the residential neighbourhood. The windowless facades also enhance the sculptural feature of the building and emphasizes the rough materiality of the red concrete. The dome is made of a copper like metal amidst green roofs.   IMAGES    

Interim report Januari-September 2017

Ixat Intressenter AB (publ) (”Ixat” eller “Bolaget”) redovisar i dag sitt konsoliderade resultat för perioden januari-september 2017.   Vd-kommentar: ”Tredje kvartalet var stabilt med en positiv försäljningsutveckling och förbättrat resultat med fortsatta investeringar inom IT och kvalitet. Vi ökade omsättningen med 8% och förbättrade EBITDA med 35% efter engångskostnader. Samtidigt präglades kvartalet av ett fortsatt omfattande omställningsarbete med IT-investeringar och integration av förvärv, som tynger ner verksamheten.” Finansiella höjdpunkter för tredje kvartalet: · Nettoomsättningen uppgick till 1 306 MSEK (1 215) · EBITDA före engångsposter uppgick till 60 MSEK (58) · EBITDA uppgick till 50 MSEK (37) · Rörelseresultatet uppgick till -3 MSEK (-6) · Resultatet före skatt uppgick till -32 MSEK (-29) · Periodens kassaflöde uppgick till -56 MSEK (-25) Rapporten finns tillgänglig på För övrig information kontakta: Olof Fransson, CFO Cabonline Group tel. +4670 517 2022 Pernilla Oldmark, CCO Cabonline Group tel. +4670 426 4545 Denna information är sådan information som Ixat Intressenter AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning 596/2014. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 20 november 2017. Om Cabonline Group Cabonline Group  är en av Europas ledande teknik och serviceleverantörer till taxi och transportbranschen. I Sverige och Norge är ca 3500 åkerier anslutna med tillsammans ca 7000 fordon under olika varumärken, bl.a. TaxiKurir, Taxi 020, Norgestaxi, TOPCAB, Taxi Skåne och Sverigetaxi. Åkerierna får genom Cabonline Group attraktiva kundavtal, branschledande teknikutveckling och tillgång till stordriftsfördelar och infrastruktur. Gruppen omsätter cirka 5,6  miljarder kronor och utför drygt 60 000 resor per dygn. Ixat Intressenter AB (publ) är moderbolag i Cabonline-koncernen. Ixat Intressenter AB (publ) emitterade den 12 juni 2017 säkerställda obligationer om SEK 1 550 miljoner. 

Getinge installs its 1,000th Hybrid operating room

It was when the West Virginia University (WVU) Heart and Vascular Institute, in Morgantown, W.Va., recently installed three new, state-of-the-art Hybrid ORs that Getinge passed 1,000 installations. Designed for patients requiring vascular or structural heart procedures, Hybrid ORs combine a traditional operating room with a catheterization lab and imaging suite. “Having a Hybrid OR gives us the flexibility and space to bring cardiologists, vascular surgeons and heart surgeons together to address a patient’s condition and use the most advanced technology to optimally care for that patient and create the best outcome for them,” says Luke Marone, M.D., Co-director of the WVU Heart and Vascular Institute, Chief of the Division of Vascular and Endovascular Surgery, and Chief of Vascular Interventional Radiology Services at WVU Medicine. “We believe our investment in these multiple new Hybrid ORs is worth it because the integration of X-ray technology, flexible movement technology and ultrasound technology allows us to perform the most advanced cardiovascular procedures with the greatest confidence.” The future of surgeryThe Hybrid OR allows clinicians to diagnose and treat in a single location, reducing risk and delays, improving patient safety, and ultimately reducing costs. Many different procedures – cardiovascular, neurosurgery, oncology, orthopedic surgeries, urology and traumatology – can benefit from real-time diagnostic imaging. “By switching to a Hybrid OR, you get a single surgical workspace that combines imaging equipment with a multifunctional surgical table, that doesn’t only meet the needs of multiple surgical disciplines but also balances the need for panning when used for advanced imaging”, says Frédéric Pette, President Surgical Workflows, Getinge. “We offer all of the products and systems a hospital need to fully equip a Hybrid OR, in order to provide patients with the best possible care. A Hybrid OR is an investment in both better patient outcomes and staff satisfaction. It is truly the future of surgery”. About Hybrid ORsIn a Hybrid OR, advanced diagnostic imaging equipment is contained within a traditional OR environment, creating a multidisciplinary space that enables healthcare professionals from different specialties to diagnose and treat patients in the same location and perform both open and minimally invasive procedures. The advanced room design allows for a patient to transition from an interventional to a surgical procedure without needing to be transported to another setting. Within the Hybrid OR, procedures can be performed efficiently, allowing for reduced time in the OR setting and improved clinical outcomes for patients. Other benefits of a Hybrid OR include faster diagnosis and treatment of patients, more efficient workflows and streamlined clinical efficiencies. About Getinge’s experience and expertise with Hybrid ORsGetinge is a global leader in providing complete solutions for the Hybrid OR, having installed 1,000 integrated Hybrid ORs worldwide. Getinge helps hospitals plan and install complex Hybrid ORs and address implementation challenges, including coordinating and integrating equipment provided by different vendors into a functioning overall space. Getinge’s Hybrid OR design team works closely with other vendors, hospital staff and architects to discuss capabilities and options for all possible configurations that can be utilized to gain maximum workflow and efficiencies. Getinge’s state-of-the art 3D OR planning tool helps hospitals conceptualize and visualize the Hybrid OR before installation begins. Getinge offers a full range of products for Hybrid ORs, including the state-of-the-art Maquet Magnus OR Table System. Serving as the centerpiece of a Hybrid OR, Maquet Magnus supports advanced diagnostic 360° 3D imaging and can be used for both minimally invasive endovascular procedures and open surgery procedures. The company also offers Maquet Variop Modular Wall Systems, surgical lights, ceiling supply units, anesthesia and heart-lung machines, cardiovascular and endovascular medical devices, and Tegris, its state-of-the-art OR integration solution. These products are designed for use in the Hybrid OR together with imaging systems from other partners. Read more about our products here . For more information, please contactAnna AppelqvistVice President Corporate CommunicationPhone: + 46 (0)10 335 5906Email: About GetingeGetinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the every-day life for people, today and tomorrow.

Zubsolv® receives authorization for treatment of opioid dependence in Europe

Uppsala, Sweden – November 20, 2017 – Orexo AB (publ.) today announce that the European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and naloxone), a novel rapidly-disintegrating treatment option for opioid dependence. Zubsolv, is a sublingual tablet licensed for people with opioid dependence within a framework of medical, social and psychological treatment. It is the first such therapy to be approved in a choice of six different strengths in Europe. This offers the potential for finer titration and individualized dosing with potentially fewer tablets compared with existing opioid dependence medicines. Opioid use disorder is a chronic, relapsing-remitting condition that places a large burden on the individual and society. With an estimated 1.3 million high-risk opioid users in 2016, opioid dependence is a serious health concern in Europe where heroin accounts for a majority of the illicit opioid misuse. Nikolaj Sørensen, President and CEO at Orexo AB, said: “Our ambition is to make Zubsolv available to patients outside the US, and this approval is an important step in realizing this goal. We look forward to continuing our journey with Mundipharma, our partner, reaching out with this unique product globally and introducing an important new option in the care of those suffering from opioid dependence.” The approval does not trigger any milestone payment. Next milestone payment is expected when the commercialization of Zubsolv is initiated. Orexo is also entitled to receive further milestone payments as well as tiered royalties on future net sales. For further information, please contact: Orexo AB (publ.)Nikolaj Sørensen, President and CEOTel: +46 (0)18 780 88 00E-mail: About Orexo Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden. About Zubsolv Zubsolv (buprenorphine and naloxone) sublingual tablet is licensed in the US for the treatment of opioid dependence and used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. It was submitted to the EMA for marketing authorisation following the completion of a registrational bioequivalence study compared to reference product Suboxone® tablet (buprenorphine and naloxone). For more information about Orexo please visit, You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites and  ----------------------------------------------------------------------

Nel ASA: Preliminary result of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Nel ASA: Preliminary result of the Subsequent Offering (Oslo, 20 November 2017) Reference is made to the stock exchange announcement dated 7 November 2017 regarding the commencement of the subsequent offering of up to 10,000,000 new shares (the "Offer Shares") in Nel ASA ("Nel" or the "Company") at a subscription price of NOK 2.50 per share (the "Subsequent Offering"). The subscription period ended today on 20 November 2017 at 16:30 hours (CET). A preliminary counting indicates that the Company has received subscriptions for approximately 79.1 million Offer Shares in the Subsequent Offering. The allocation of the Offer Shares in the Subsequent Offering is expected to be resolved by the Company during 21 November 2017, in accordance with the allocation criteria set out in the Company's prospectus dated 6 November 2017. The final result of the Subsequent Offering will be published shortly thereafter, and subscribers who are allocated Offer Shares will receive a letter with the number of allocated Offer Shares and the corresponding subscription amount to be paid by each of the subscribers. Arctic Securities and Carnegie acted as joint bookrunners in the Subsequent Offering. Advokatfirmaet Schjødt AS acted as Norwegian legal counsel to the Company. ENDS For additional information, please contact: Jon André Løkke, CEO, +47 9074 4949 Bent Skisaker, CFO, +47 468 21 693 About Nel |       Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today. Important information:  The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Carnegie is acting for the Company and no one else in connection with the Private Placement and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement and/or any other matter referred to in this release. Forward-looking statements:  This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Qliro Group sells Health and Sports Nutrition Group

“Following the sale of HSNG, Qliro Group has achieved the structure that we envisioned when we revised our strategy in January. The migration to online is moving faster than ever before and our three core business areas, CDON Marketplace, Nelly and Qliro Financial Services, are well positioned to benefit from this. We can now fully focus on and invest in our core businesses, including expanding Qliro Financial Services”, says Marcus Lindqvist, President and CEO of Qliro Group. HSNG was established in 1996 and was acquired by Qliro Group in 2008. Since the acquisition, HSNG has grown from a turnover of approximately SEK 110 million to almost SEK 800 million during the last twelve months up to 30 September 2017. “As part of Qliro Group, HSNG has established itself as a leading online provider of sports nutrition in the Nordic region with a strong portfolio of own brands. We now look forward to continuing to cooperate with the company as a partner to both CDON Marketplace and Qliro Financial Services”, says Marcus Lindqvist, President and CEO of Qliro Group. The transaction is subject to approval from the competition authorities in Sweden, Norway and Austria and is expected to be completed during the first quarter of 2018. The enterprise value of HSNG in the transaction is SEK 360 million on a cash and debt free basis and with a normalized working capital at closing. Qliro Group’s book value of the shares in HSNG was SEK 223.8 million at the end of the third quarter 2017. The effect on the results of the transaction will be determined at closing. HSNG is expected to be reported as an item under discontinued operations from the fourth quarter 2017. This information is information that Qliro Group AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 01.00 a.m. CET on 21 November 2017. Carnegie Investment Bank AB is acting financial adviser and Advokatfirman Cederquist is acting legal adviser to Qliro Group in the transaction. For more information, please visit, or contact:Marcus Lindqvist, CEOTel: +46 (0)10 703 20 00  Questions from media, investors and research analysts:Erik Löfgren, Head of CommunicationsTel: +46 70 080 7506E-mail:,  About Health and Sports Nutrition GroupHealth and Sports Nutrition Group operates the online stores ( in Finland, in Denmark and in Austria and other EU countries),, (with limited operations) and conducts wholesale operations through Fitness Market Nordic. Gymgrossisten also has franchised physical stores. Together, the internet stores registered 23.6 million site visits and received 1.2 million orders in 2016.   About Qliro GroupQliro Group is a leading Nordic e-commerce group in consumer goods, lifestyle products and related financial services. Qliro Group operates CDON.COM (the leading Nordic marketplace), and NLYman (fashion), Gymgrossisten and (health and training), and Qliro Financial Services. The Group had sales of SEK 4 billion in 2016. Qliro Group’s shares are listed on the Nasdaq Stockholm in the midcap segment under the ticker symbol QLRO.

21st Century Oncology chooses Elekta for replacement of radiation therapy devices

STOCKHOLM, November 21, 2017 – Elekta (EKTA-B.ST) announces that 21st Century Oncology, the largest radiation oncology provider in the U.S., will replace several of its existing linear accelerators, as well as treatment planning software and oncology information systems, with advanced cancer treatment solutions from Elekta. The agreement includes Elekta’s Versa HD™  linear accelerators, which combines high definition dynamic radiosurgery and precision radiation therapy treatments throughout the body in a single platform. It also includes Elekta’s MOSAIQ®  oncology information system – the Best in KLAS award winner – that enables optimization in health care practices through intelligent automation and actionable analytics. 21st Century Oncology will also upgrade to Monaco® , a state-of-the-art treatment planning solution that powers efficient high definition treatment planning with gold-standard accuracy. Gustavo Olivera, PhD, 21st Century Oncology’s Chief Technology Officer, and Dr. Arie Dosoretz, a 21st Century Oncology member of the Office of the Chief Medical Officer, who oversees clinical operations, says: "Elekta’s portfolio is well aligned with our strategic needs. Our partnership offers us a tremendous opportunity to update our domestic and international fleet of machines and continue to adapt our clinical offerings to an ever-evolving field. We are excited to implement our vision together now and in the years to come." Dr. Constantine Mantz, 21st Century Oncology’s Chief Medical Officer, says: “Our ambition is to provide state-of-the-art radiation therapy. Upgrading to Elekta’s innovative technology is as much an investment in our patients as it is in equipment. With this suite of solutions, we will be able to deliver high quality care for our patients in a highly efficient and integrated manner for our treatment centers.” Peter Gaccione, EVP Region North America at Elekta, says: “We are very happy that 21st Century Oncology has chosen Elekta, a company that shares and supports their goal to offer the most advanced cancer treatment in a patient-centric setting focused on continuous innovation.” USD 22 million has been booked in the second quarter of Elekta’s fiscal year 2017/18. First deliveries of the new order are scheduled to begin in April, 2018, to centers in the USA. To learn more about these solutions, visit:Versa HD Monaco # # # For further information, please contact:Gert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-mail: gert.vansanten@elekta.comTime zone: CET: Central European TimeTobias Bülow, Director Financial Communications, Elekta ABTel: +46 722 215 017, e-mail: tobias.bulow@elekta.comTime zone: CET: Central European Time This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on November 21, 2017. (REGMAR)About ElektaElekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm.

New study results support use of DiviTum® for evaluation of pancreatic cancer

The proof of concept study, including 404 patients, provides evidence for using DiviTum as a dynamic biomarker before and during therapy to give important answers regarding prognosis and how effective therapy is. Biovica’s assay was prognostic for overall survival in all patients. For patients receiving therapy ahead of surgery, preoperative low DiviTum values demonstrated significantly higher overall survival compared to patients with high values. Pancreatic cancer is one of the deadliest forms of cancer. Hence, tools that can provide more and early information regarding the disease is in great need. With better and faster evaluation of treatments Biovica aims to provide a better tool when evaluating therapy options. The study provides additional evidence and future expanded clinical potential outside of breast cancer for DiviTum. The DiviTum assay determines thymidine kinase activity in a blood sample and is a practical, non-invasive tool for predicting outcome and monitoring efficacy in solid tumors. Biovica have an ongoing trial program including more than 10 clinical studies and 1 500 patients to document the unique capabilities of the assay in solid tumors. “It is very important to know if a therapy is effective or not. The results provide evidence for using DiviTum to give accurate prognosis and guidance regarding therapy efficacy in patients with pancreatic tumors. Our study is the first to demonstrate that a blood based marker like DiviTum can give important prognostic information to clinicians treating pancreatic cancer and become a tool for early evaluation of neoadjuvant therapy efficacy and treatment options. Additionally despite the fact that CA 19-9 is still the gold standard biomarker in pancreatic cancer, for patients with low CA 19-9 or CA 19-9 non-secretors, the S-TK assay could be an alternative screening marker”, says Dr Klaus Felix, Ph.D, Department of General Surgery, University of Heidelberg. “The results presented from our collaboration with Dr Felix at the University of Heidelberg demonstrates the utility of DiviTum for precise prognosis and therapy efficacy evaluation for patients with pancreatic cancer. This builds on already published data on other tumors and provides evidence beyond our extensive trial program in breast cancer, with the aim for DiviTum to become a standard tool for predicting outcome and early efficacy evaluation for patients with specific solid tumors”, says Anders Rylander, CEO Biovica.

Interim report Q3 2017

Third quarter (July-Sep 2017) · Revenue increased by 26% to MEUR 19.3 (15.3) · B2B Revenue increased by 31% to MEUR 10.1 (7.7) · EBITDA increased by 44% to MEUR 4.2 (2.9) · EBITDA margin increased to 22% (19%) · EBIT increased by 44% to MEUR 3.9 (2.7) · Earnings after tax amounted to MEUR 3.6 (2.3) · Earnings per share, after tax, from continued operations amounted to EUR 0.08 (0.05) · First Time Depositors (FTDs) increased by 40% to 63.9 thousand (45.7) · Revenue increased by 15% to MEUR 52.8 (45.9) · B2B Revenue increased by 18% to MEUR 26.8 (22.7) · EBITDA increased by 21% to MEUR 10.4 (8.6) · EBITDA margin increased to 20% (19) · EBIT increased by 20% to MEUR 9.6 (8.0) · Earning after tax amounted to MEUR 9.0 (7.9) · Earnings per share, after tax, from continued operations amounted to EUR 0.20 (0.19) · First Time Depositors (FTDs) increased by 31% to 177.7 thousand (135.9) · On July 11th, Aspire Global was listed for trading on the NASDAQ First North Premier in Stockholm, Sweden. The offering price had been set to SEK 30 per share, corresponding to a value of the company’s shares of SEK 1,323 million after the completion of the offering. The offering was significantly over-subscribed and trading commenced on Tuesday July 11th. On August 3rd Pareto Securities had fully exercised the over-allotment option regarding 1,641,977 existing shares in the company. On September 1st Aspire Global appointed FNCA Sweden AB as the company’s new certified adviser. · On September 12th, Aspire Global announced the withdrawal from the Australian market following the country’s new gaming legislation. · Neolotto Ltd, a company owned 38% by Aspire Global, was granted a nationwide license in Germany for charity lotteries. Shareholders in Neolotto decided, on August 30th, to grant NeoLotto a convertible loan of €4,500 thousand for exploring this business potential already in 2017. Aspire Global’s part of the convertible loan amounts to EUR 2,250 thousand. · On September 27th, Aspire Global entered the newly regulated Portuguese market through a strategic partnership with public company Cofina, one of the largest Media Groups in Portugal. The initiative is in line with the Aspire Global’s long term strategy to focus on strong partnerships in regulated markets. · On November 20th, Aspire Global’s board of directors approved an investment in a company that will launch Mr. Play, a new fully regulated casino and sports betting brand managed by a select group of industry veterans. Apart from becoming a material owner in the venture with 40% of the shares, Aspire Global is expected to generate revenues from providing the technology and the core operational services on market terms. Based on business milestones the group of shareholders will finance the new company up to the tune of EUR 4 million, of which Aspire Global’s part will be up to EUR 2 million.  Interim period (Jan-Sep 2017) Significant events during and after the third quarter Teleconference Today, on November 21th 2017, at 10:00 (CET), the company CEO, Tsachi Maimon, and CFO, Motti Gil, will be presenting the report and answering questions at a teleconference (in English), which will be webcasted live through the following link: The meeting, including the Q&A-session, is also available by calling one of the telephone numbers below. The complete interim report and the presentation material is available at . Sweden: +46 8 566 426 62                       UK: +44 20 3008 9801                       US: +1 855 753 2236 Letter from the CEO, Tsachi Maimon I am pleased to report yet another quarter of strong growth in both revenue and profit; quarter on quarter as well as year on year. We have also expanded our customer base, complementing original key accounts with a number of new partnerships that have quickly reached sizable levels. As we execute on our strategy; broadening our offering with new verticals (sport) and entering new regulated markets through strong local partnerships, we are well on our way of reaching double digit growth year on year. Great scalability enabling fast growth through new partnerships During the third quarter, we signed 4 new partnerships. We also started operating in our sixth regulated market, Portugal, together with our local partner Cofina, a public media company. The online casino is up and running, generating significant streams of new players, soon to be followed by the upcoming launch of our new sportsbook product. The Cofina media house owns several television channels as well as newspapers and magazines (online and print), amongst which the country’s biggest sport magazine, “Record”. We provide them with a great iGaming platform, allowing them to focus on what they do best; marketing attractive content to their target group. Our business model has great scalability in the sense that new partnerships easily generate new revenue streams without major investments or start-up costs from our side. Maintaining a leading position with an offering at the forefront Since the end of the summer we have added proprietary Jackpot slot and charity gaming to our offering, launched a new casino app and finalized a successful overhaul of our proprietary brand Karamba. We are currently fine-tuning our sports book product which is to be launched in Q4, both in our most recent market Portugal and through As we improve or add new verticals, enhancing our B2B offering (the Aspire Global platform), we attract new partners while existing ones are easily able to target a whole new audience.  Geographic expansion with focus on regulated markets During the past year, we have been observing the development in Australia as the market conditions were about to change. Once the authorities voted for an amendment of its current gaming legislation, we chose to withdraw from the country in favor of the long-term potential in regulated markets. Going forward, we are thus focusing on obtaining additional gaming licenses in regulated markets; a complex process indeed, but well worth our while as it creates a considerable competitive advantage. As we enter additional regulated markets, we expect to establish new partnerships with well-established media companies leveraging their strong brands through our offering, same as Cofina. Going forward We are currently monitoring the development in Portugal and the upcoming launch of Sportsbook, while preparing to enter additional regulated countries as they become accessible. We continue to look actively for acquisition opportunities and new projects, allowing us to migrate popular casinos to our own platform or leverage our strong position in new profitable ways. An exciting example of such initiatives is our investment in Mr. Play in which we have identified an opportunity to team up with industry veterans with a proven track record. We will continue to actively look for other acquisition opportunities and in this context review our financing options, including different sources of debt financing. For more information, please contact: Tsachi Maimon, CEO, Tel: +356-79777898 or email: Motti Gil, CFO, Tel: +972-73 372 3154 or email:   About this information Aspire global discloses the information provided herein pursuant to the Securities markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication by the contact person above at 08:00 am (CET) on November 21th, 2017. About Aspire Global Founded in 2005, Aspire Global offers a comprehensive iGaming solution for operators and white labels, including a complete suite of services for casino and sportsbook, multilingual CRM, payments and risk control, support call center, VIP management, acquisition optimisation and a robust, market-leading platform. Aspire Global also holds licenses in regulated markets including the UK, Denmark, Belgium, Italy and Malta. Aspire Global is listed on NASDAQ First North Premier under ASPIRE. Certified Adviser: FNCA Sweden AB

NeuroVive Pharmaceutical AB Interim report January - September 2017

Significant events July-September 2017  · NeuroVive received positive feedback from the European Medicines Agency (EMA) regarding the NeuroSTAT development plan. · NeuroVive signed a private placement agreement with Esousa Holdings LLC totalling SEK 4.5 million excluding transaction costs. · NeuroVive hosted a Mitochondria Day at IVA in Stockholm to raise awareness of mitochondrial disorders. Important events after the end of the period  · NeuroVive received a positive opinion from the the European Medicines Agency’s (EMA) Committee on Orphan Drugs (COMP) on granting orphan drug designation for KL1333. · Greg Batcheller, NeuroVive’s Chairman of the Board for the past 17 years, resigned on 6 November. David Laskow-Pooley was elected new Chairman. · On November 3, NeuroVive conducted a directed new share issue to Floyd Associates Europe Limited totaling SEK 5.3 million excluding transaction costs. · NeuroVive and Lund University were granted funding by the Swedish Foundation for Strategic Research (SSF) for collaboration on liver cancer research. · NeuroVive signed a collaboration agreement with the University of Florida regarding the development of TBI biomarkers. · NeuroVive presented the results from preclinical TBI trials related to the NeuroSTAT project at the 2017 Nordic Neurotrauma Conference. · NeuroVive presented its innovative metabolic regulators for the non-alcoholic steatohepatitis (NASH) liver disease at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) held on 20-24 October 2017, in Washington DC. · NeuroVive’s partner, the Children’s Hospital of Philadelphia (CHOP), was awarded funding by the US National Institutions of Health (NIH) to study NeuroVive’s NVP015 compounds as countermeasures against chemical threats. Financial information  Third quarter (July-September 2017)  · Net revenues were SEK 0 (0) and other operating income was SEK 397,000 (16,000) · Loss before tax was SEK 13,179,000 (loss: 34,290,000) · Loss per share* was SEK 0.26 (loss: 0.86) · Diluted loss per share** was SEK 0.26 (loss: 0.86)  First nine months (January-September 2017)  · Net revenues were SEK 27,000 (0) and other operating income was SEK 550,000 (90,000) · Loss before tax was SEK 56,824,000 (loss: 57,265,000) · Loss per share* was SEK 1.04 (loss: 1.42) · Diluted loss per share** was SEK 1.04 (loss: 1.42)  * Profit/loss for the period divided by average number of shares before dilution at the end of the period. ** Profit/loss for the period divided by average number of shares after dilution at the end of the period Please find the complete interim report attached below. This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, at 08:30 a.m. CET on 21 November 2017.  NeuroVive Pharmaceutical AB (publ)   Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) About NeuroVive  NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

Sectra wins French PACS deal with Imapôle Lyon-Villeurbanne as two clinics merge

“To us, it was important to find a future-proof vendor recognized for efficient solutions,” says Mr. Lounis, Radiology Department Manager at Imapôle Lyon-Villeurbanne. “Sectra’s solution has a proven track record of high system availability and support for efficient radiology workflows, which aligns well with our strategy. Its future-proof technology and the possibility to smoothly extend the solution to other departments are important aspects of meeting the future needs of Médipôle Lyon-Villeurbanne.” “Sectra is distinguished by being highly innovative as a company,” says Dr. Emonet, Co-Manager of Imapôle Lyon-Villeurbanne. “Also, it’s beneficial to be able to secure a consolidated patient pathway at Médipôle Lyon-Villeurbanne. In addition, the imaging element of the solution will enable us to provide greater value to our patients on a daily basis.” “Sectra’s experience of large-scale projects impressed us and will be valuable given the future size of Imapôle Lyon-Villeurbanne,” says Dr. Lebas, Co-Manager of Imapôle Lyon-Villeurbanne. “The flexibility of Sectra PACS is unique and enables each radiologist to work efficiently according to their own preferences. The tools offered in oncology will also add value.” The contract includes Sectra PACS for reviewing radiology images at Médipôle Lyon-Villeurbanne. The Sectra solution will handle the approximately 150,000 examinations performed at the clinic every year. The contract is sold as a service (SAAS). About Sectra PACSSectra PACS is optimized for high-production environments with stability and usability in focus. It is designed to shorten report turnaround times, enhance result distribution workflows, and improve communication between radiology and referring departments. For four continuous years, Sectra PACS has won the customer satisfaction award “Best in KLAS” for US hospitals with over 200 beds and for three years in a row the “Best in KLAS” for Global (Non-US) PACS. Sectra PACS is part of Sectra’s complete enterprise imaging offering, which is modular and supports the most image-intense departments—radiology, pathology, cardiology and orthopaedics. Being built on the same technical platform, customers can easily extend a departmental solution to create a comprehensive VNA and enterprise image management solution without major investments or the replacement of existing components. Experience the solutions at RSNA 2017Sectra’s solutions for radiology imaging will be showcased at RSNA in booth #6113. Read more and book a meeting with Sectra at RSNA .

Nel ASA: Final result of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Nel ASA: Final result of the Subsequent Offering (Oslo, 21 November 2017) Reference is made to the stock exchange announcement dated 20 November 2017 regarding the preliminary result of the subsequent offering of up to 10,000,000 new shares (the "Offer Shares") in Nel ASA ("Nel" or the "Company") at a subscription price of NOK 2.50 per share (the "Subsequent Offering"). The subscription period in the Subsequent Offering expired on 20 November at 16:30 CET. By the end of the subscription period, the Company had received valid subscriptions for a total of 79.1 million Offer Shares, equivalent to a value of NOK 197.8 million. Hence, 10 million Offer Shares will be issued, and upon the registration of the new share capital, the Company will have 998,714,952 shares issued, each of par value NOK 0.20. Notifications of allocated Offer Shares in the Subsequent Offering and the corresponding amount to be paid by each subscriber will be set out in a separate letter to each subscriber to whom Offer Shares have been allotted. The allocation letters are expected to be sent today. No primary insiders have received allocation of Offer Shares in the Subsequent Offering. Arctic Securities and Carnegie acted as joint bookrunners in the Subsequent Offering. Advokatfirmaet Schjødt AS acted as Norwegian legal counsel to the Company.  ENDS For additional information, please contact: Jon André Løkke, CEO, +47 9074 4949 Bent Skisaker, CFO, +47 468 21 693 About Nel |       Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today. Important information:  The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia). This release is an announcement issued pursuant to legal information obligations, and is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Carnegie is acting for the Company and no one else in connection with the Private Placement and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement and/or any other matter referred to in this release. Forward-looking statements:  This release and any materials distributed in connection with this release may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

EQT Mid Market joins forces with Epidemic Sound

· EQT Mid Market joins forces with Epidemic Sound, a new breed of music company that collaborates with musicians all over the world to produce quality music that soundtracks everything from TV and film productions to online videos on YouTube or Facebook - consumers can also listen to tracks on streaming platforms such as Spotify · EQT Mid Market will, together with the current shareholders, support Epidemic Sound’s growth ambitions by leveraging on EQT’s global footprint, experience in scaling high-growth businesses as well as digital expertise The EQT Mid Market Europe fund (“EQT Mid Market”) today announced that it is partnering up with Epidemic Sound (or “the Company”). Together with Oscar Höglund, Co-founder and CEO, his team and the A-round lead investor Creandum (which will increase its ownership in conjunction with the transaction), EQT Mid Market will support an accelerated growth plan. Following the investment, the approximate ownership split is the EQT Mid Market fund 40%, Epidemic Sound founders 40% and Creandum 20%. Founded in 2009 and headquartered in Stockholm, Sweden, Epidemic Sound is a new breed of music company, offering high-quality music, primarily targeting video content production clients, in-store music and streaming platforms. Epidemic Sound works closely with talented composers and musicians across genres and geographies, whose music makes up the Company’s cloud-based platform, containing over 30,000 tracks. Epidemic Sound is seeing increased demand for quality soundtracks from a wide range of creators - from traditional TV broadcasters to professional online creators, such as YouTubers and those who create videos for Facebook. Through a subscription-based model, customers are given access to an extensive music library for usage in content production, with all rights included worldwide and irrespectively of the platform. EQT Mid Market will support Epidemic Sound’s growth journey through further investments in the product platform and continued international expansion with the mission to release Epidemic Sound’s full growth-potential in both existing and new end-markets. “EQT Mid Market has followed Epidemic Sound for years and it is truly one of Sweden’s ‘best kept secrets’ with a unique value proposition to its customers in structurally high-growing market verticals. The success is built on a combination of two of Sweden’s strongest export industries; music and tech. The Epidemic Sound founders have, in an impressively entrepreneurial way, combined these two into a very compelling product offering supported by a highly scalable business model. EQT’s geographic reach and vast expertise within tech and digitalization will support Epidemic Sound’s accelerated growth journey globally and we are excited to join forces with Oscar and the team”, says Johan Dettel, Partner at EQT Partners and Investment Advisor to EQT Mid Market. Oscar Höglund, CEO at Epidemic Sound, comments: “Over the past couple of years two things have happened. We have seen an explosion of online video and a huge increase in demand for quality soundtracks - both activity based music and more mainstream hit music. Teaming up with EQT Mid Market supercharges our business and thinking, and more importantly allows us to move towards our goal of making the music industry a better place to be, at a much faster rate”. White & Case served as legal advisor to EQT Mid Market, BCG as commercial consultant and KPMG as finance and tax advisor. Contacts:Johan Dettel, Partner at EQT Partners, Investment Advisor to EQT Mid Market, +468 506 55 350EQT Press Office, +468 506 55 334 About EQTEQT is a leading alternative investments firm with approximately EUR 37 billion in raised capital across 24 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: About Epidemic SoundEpidemic Sound is a new breed of music company founded in 2009 with a mission to make the music industry a better place. It collaborates with musicians all over the world to produce quality music that soundtracks people’s lives. Our music can be heard soundtracking everything from TV and film productions to online videos on YouTube or Facebook - consumers can also listen to tracks on streaming platforms such as Spotify. With music spanning over 180 genres and 30,000 tracks and all music available in prime time broadcast quality, the creative possibilities are endless. Listen to our music at: About CreandumCreandum is a leading European venture capital firm, focusing on innovative and fast-growing technology companies, primarily in the tech sector. The Creandum funds have over €400M under management and are advised by the Creandum Advisory companies with offices in Stockholm, Berlin and San Francisco. Creandum have over the last decade invested in more than 60 companies including Spotify, Klarna, iZettle, Kry, Vivino and many others. More info:

Edvince AB granted EU Orphan Medicinal Product Designation for EDV2209 in treatment of non-traumatic subarachnoid hemorrhage

Orphan medicinal product designation can be granted by the European Commission for diseases with a prevalence of less than 5 individuals per 10,000. Orphan medicinal product designation status for a drug is valuable, and comes with many developmental and market benefits. For example, a prioritized and subsidized regulatory process with the European Medicines Agency (EMA) is available. Most importantly, orphan designation implies a potential for up to 12 years exclusivity on the European market after a formal market approval. -       We are extremely happy to receive this positive response from EMA and the European Commission. Along with the orphan designation granted by the FDA in august 2017, this is a very important milestone in the development of a new treatment for subarachnoid hemorrhage. Since Edvince is committed to bring this therapy to patients in need, the orphan medicinal product designation will accelerate and facilitate this process, says Carl-Magnus Högerkorp, CEO, Edvince. Subarachnoid hemorrhage is a condition that affects around 50 000 individuals every year in Europe, typically as a consequence of a ruptured brain aneurysm, leading to a bleeding in the brain. There is a huge unmet medical need in the management of subarachnoid hemorrhage. Up to 40-50% dies and 3 out of 5 that survives will not return to a normal life. Subarachnoid hemorrhage triggers events that days later will affect the blood supply to parts of the brain resulting in brain damage. EDV2209 prevents these events from occurring and maintains the blood supply to the brain.

Sandvik Capital Markets Day with strategic focus on stability, profitability and growth

Today, at the Capital Markets Day in Tübingen, Germany, Björn Rosengren, President and CEO and Tomas Eliasson, Executive Vice President and CFO of Sandvik, presented the key focus areas for the different businesses based on Sandvik’s fundamental strategic principle of stability and profitability before growth. “During the past two years we have set the fundamentals in terms of moving into a decentralized structure, improved our performance review process, consolidated the business portfolio and virtually completed the supply chain optimization program. This, in combination with a stronger market environment, has resulted in improved profitability for the group. We have strengthened the balance sheet, enabling those businesses which are both stable and profitable to increasingly shift focus to growth. Each of the more than 30 different operations in Sandvik has its separate opportunities and challenges and must act accordingly. I expect each business to continuously improve and I am convinced there are more efficiencies to be gained”, says Björn Rosengren, President and CEO of Sandvik. At the Capital Markets Day the business area presidents presented the key focus areas for their respective operations: Sandvik Machining Solutions, Klas Forsström · Continued focus on strengthening the core business of cutting tools. · High focus on R&D, product development and operational excellence. · Increased share of round tools, services and customized offerings. · Accelerated growth through development of adjacent offerings. · Commercialization of the capabilities in Additive Manufacturing. · Broadening of digital service offerings. · Continued strategic focus on technical innovation and customer intimacy. · Increased focus on Mergers & Acquisitions. Sandvik Mining and Rock Technology, Lars Engström · Growth · Further growth in the aftermarket business through new or improved customer offerings such as e-solutions and increased productivity through data-driven predictive maintenance. · Leading position in customer offering for automation and digital solutions for the mining and rock excavation industries. · Improve profitability through e.g. grow the aftermarket business implying reduced earnings volatility.  Sandvik Materials Technology, Göran Björkman · Restore profitability both short- and mid-term. · Short-term this includes the recently implemented decentralized structure and cost reductions. · Mid-term this includes new product development, operational excellence and optimization of product mix. · Accelerate growth in product areas Powder and Kanthal. Tübingen, 21 November 2017Sandvik AB For further information, please contact Ann-Sofie Nordh, Vice President Investor Relations, tel +46 8 456 1494 or Pär Altan, Vice President External Communications, tel +46 70 616 20 24.

ABG Sundal Collier ASA has been approved as a member of NGM

“Today it is our pleasure to announce that ABG has been approved as a new member of the exchange. The fact that ABG has become a member of the exchange is another sign of the strength in NGM’s offer. We already offer the largest selection of exchange traded products in the Nordics and now we also have more than 200 listed Nordic companies. The value for banks of being connected to NGM increased further following the migration of AktieTorget into our trading system”, says Tommy Fransson, Deputy CEO of NGM. For more information, please contact: Tommy Fransson                                                       Deputy CEO                                                               Nordic Growth Market                                                                        +46 8 566 390 49                                                     Karl Berglund Managing Partner Sweden ABG Sundal Collier +46 8 566 286 47         Daniel Lundqvist Head of Sales Trading Sweden ABG Sundal Collier +46 8 566 286 06 About Nordic Growth Market   NGM is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange was founded in 1984 and is today a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies wishing to list shares. For more information about NGM, visit Follow us on LinkedIn and Twitter. About ABG Sundal Collier ABG Sundal Collier is an independent Nordic investment banking powerhouse, established for more than 30 years, founded on a hard-working partnership culture and the ability to attract and develop top talent. Our corporate advisory team offers unparalleled transaction experience in combination with the value of our long-standing connections to regional and international investors and corporations. Our market-leading Nordic and international securities distribution platform provides access to financing for corporates and is well set up for naturally matching trading flows and delivering best execution for clients. 

Future issues in focus at the Pandox Hotel Market Day 2017

Pandox introduced the hotel market day already in 1996 with the aim to reflect upon and analyse important macro trends and to contribute to added know-how in the hotel industry. Since then, the hotel market day has developed into a dynamic meeting place for decision makers within the international hotel industry. The interest is for the Pandox Hotel Market Day is great. This year the event gathers more than 300 participants from almost 15 countries. The event is aimed at participants from the hotel industry, institutional investors, analysts and media. Please visit for a detailed agenda and more information about the speakers. Here, the presentation material will also be published. Recorded versions of Pandox’s CEO Anders Nissen’s presentations will also be made available at the same location after the event. The presentations will start at 13:00 CET and end around 18:15 CET. FOR MORE INFORMATION, PLEASE CONTACT:Anders Nissen, VD, +46 (0) 70 846 02 02Anders Berg, Head of Communications and IR, +46 (0) 760 95 19 40 The information was submitted for publication at 12:45 CET on 21 November 2017.About PandoxPandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio currently comprises 122 hotels with approximately 27,000 hotel rooms in eleven countries. Pandox’s business is organised into Property management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are listed on Nasdaq Stockholm.

Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017

Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, presents the company at Redeye Life Science Seminar on Friday 24 November (10:15 am CET) at Haymarket in Stockholm, Sweden. The presentation can be followed in real-time at The presentation will also be accessible after the event at and on the company page at Redeye Universe ( For further information:Cecilia Hofvander, Director Investor Relations & CommunicationsPhone +46 46 286 44 95E-mail: The information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CET on 21 November 2017. About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit .

NCC to construct Landborgen link in Helsingborg

“The Landborgen link is one piece of the puzzle to develop the city center. It is a thoroughfare that will level out height differences in Helsingborg and make it easier for pedestrians and cyclists to get around. It will also make it easier for cyclists and motorists to park and reach central areas of Helsingborg without having to travel through the city,” says Marie Holmqvist, Project Manager at the City of Helsingborg’s Urban Planning Administration. The project will be carried out in partnering form in two phases. The first phase will commence immediately, where NCC in partnership with the City of Helsingborg will study technical systems and materials, prepare the construction design, as well as a detailed time schedule and construction target price for the assignment. The second, construction phase is scheduled to begin in autumn 2018. The Landborgen link is scheduled for completion in 2020. “Building a parking garage for 600 cars and a similar number of bicycles inside Landborgen is an exciting and technically challenging project, which is highly suitable for NCC’s organization. Together with the City of Helsingborg, we will build a modern and accessible parking garage and a safe and secure thoroughfare with escalators and elevators up and down from Landborgen for pedestrians and cyclists,” says Nils Bjelm, Division Manager of NCC Infrastructure. The order value is about SEK 350 million, and is expected to be registered during the fourth quarter of 2018 in the NCC Infrastructure business area. 

Metsä Board Corporation: Managers’ transactions

Shares have transferred back to Metsäliitto Cooperative, which is a closely associated person to Metsä Board’s chairman and two members of the Board, on 20 November 2017 as part of Metsä Group’s management share incentive system. More specific information on the transaction can be found in the table below: +-----------------------------+--------------+----------------------+|Closely associated legal |Metsäliitto Cooperative ||person subject to the | ||notification:  | |+-----------------------------+--------------+----------------------+|Manager within the issuer: |Kari Jordan |+-----------------------------+--------------+----------------------+|Manager’s position within the|Chairman of the Board ||issuer: | |+-----------------------------+--------------+----------------------+|The issuer: |Metsä Board Corporation |+-----------------------------+--------------+----------------------+|Issuer’s LEI-code: |743700KKB8Q035K38488  |+-----------------------------+--------------+----------------------+|Notification type: |Initial notification |+-----------------------------+--------------+----------------------+|Reference number: |743700KKB8Q035K38488_20171120151650_5|+-----------------------------+--------------+----------------------+|Transaction date: |20 November 2017  |+-----------------------------+--------------+----------------------+|Nature of the transaction:   |OTHER |+-----------------------------+--------------+----------------------+|Instrument type:  |SHARE |+-----------------------------+--------------+----------------------+|Instrument’s name: |Metsä Board’s B share  |+-----------------------------+--------------+----------------------+|Instrument’s ISIN-code: |FI0009000665 |+-----------------------------+--------------+----------------------+|Transaction details: |Volume: 8,989 |Unit price: EUR   || | |0.00  |+-----------------------------+--------------+----------------------+|Number of transactions:  |1 |+-----------------------------+--------------+----------------------+|Aggregated transactions: |Volume: 8,989 |Volume weighted || | |average price: EUR || | |0.00  |+-----------------------------+--------------+----------------------+ METSÄ BOARD CORPORATION

Nordic Nanovector Capital Markets Day 2017

Oslo, Norway, 22 November 2017 The presentations will be held by members of the executive management team as well as selected external expert speakers, including Prof. Pier Luigi Zinzani, Associate Professor of Haematology, Institute of Haematology, University of Bologna; and Dr. Arne Kolstad, Senior consultant in Medical Oncology and Radiotherapy, Oslo University Hospital Radiumhospitalet and leading investigator of the LYMRIT 37-01 Phase 1/2 study. Highlights of the third quarter 2017 report will be presented towards the end of the programme. Highlights of the CMD: • Evolving treatment landscape and attractive opportunities for Betalutin® in NHL, where there is a significant unmet medical need; • Strong preliminary results from the Phase 1/2 LYMRIT 37-01 clinical study in 3rd line relapsed/refractory follicular lymphoma (3L R/R FL), which provide a promising outlook for Betalutin® as a differentiated, competitive product; • Rationale for and design of the pivotal Phase 2b PARADIGME trial with Betalutin®, which is intended to provide a robust means to identify the best dosing regimen and to provide the best clinical data to support filing for approval, and which the company is close to initiating; • Key learnings from an extensive market research programme that have equipped the company with valuable knowledge about the US healthcare environment, the NHL market and target customers. These insights will guide the company’s future strategy with Betalutin® to support its successful commercialisation. • Outline of the company’s strategy to maximize the value of Betalutin® in NHL. The event will start at 10:00 CET at Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo. A link to the live webcast and subsequent recording will be available at in the Investor and Media section. All presentations will be available at in the section: investors-and-media/reports-and-presentations/presentations/2017. For further information, please contact: IR enquiries Tone Kvåle, Chief Financial Officer Cell: +47 91 51 95 76 Email: Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at Forward-looking statements This announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

Nordic Nanovector kapitalmarkedsdag 2017

Oslo, 22. november 2017 Presentasjonene vil bli gitt av representanter fra selskapets ledergruppe og utvalgte eksterne eksperter, inkludert professor Pier Luigi Zinzani, førsteamanuensis i hematologi ved Institutt for hematologi ved universitetet i Bologna, og dr. Arne Kolstad, overlege i medisinsk onkologi og radioterapi ved Oslo Universitetssykehus Radiumhospitalet og forskningsleder for LYMRIT 37-01 fase 1/2 studien. Hovedpunkter fra kvartalsrapporten for tredje kvartal vil bli presentert til slutt. Presentasjonene på kapitalmarkedsdagen vil omhandle følgende hovedpunkter: • Utviklingen av konkurranseforholdene for behandling av non-Hodgkin Lymfom (NHL) og de attraktive mulighetene for Betalutin® i denne lymfekreftformen, der det er et vesentlig udekket medisinsk behov. • Sterke foreløpige resultater fra fase 1/2 LYMRIT 37-01 studien i tredjelinje gjentakende/ikke-responsiv follikulært lymfom (3L R/R FL) gir lovende utsikter for Betalutin® som et differensiert, konkurransedyktig produkt. • Rasjonalet bak og design av den avgjørende fase 2b PARADIGME-studien med Betalutin® som har som formål å identifisere det beste doseringsregimet og å levere de beste kliniske data som understøtter søknad om markedsgodkjennelse og som selskapet er nær ved å igangsette. • De viktigste læringspunktene fra en omfattende markedsundersøkelse som har gitt selskapet verdifull kunnskap om helsetjenesten i USA, NHL-markedet og hovedmålgruppen av kunder. Denne innsikten vil gjenspeiles i selskapets fremtidige strategi for vellykket kommersialisering av Betalutin®. • Selskapets strategi for å maksimere verdien av Betalutin® i NHL. Arrangementet starter kl 10:00 i Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo. Lenke til live webcast og påfølgende opptak vil være tilgjengelig på i Investor and Media-seksjonen. Alle presentasjoner vil være tilgjengelige på i seksjonen: investors-and-media/reports-and-presentations/presentations/2017. For ytterligere informasjon, vennligst kontakt: Tone Kvåle, finansdirektør Tlf: 91 51 95 76 E-post: Om Nordic Nanovector Nordic Nanovector arbeider med utvikling og kommersialisering av innovativ behandling til pasienter for å møte store udekkede behandlingsbehov og videreutvikle kreftbehandling. Selskapet har ambisjoner om å bli en ledende aktør innen utviklingen av målrettet behandling for hematologisk kreft. Nordic Nanovectors ledende legemiddelkandidat under klinisk utvikling er Betalutin®, et målrettet CD37 antistoff-radionuklid-konjugat (ARC) utviklet for å forbedre og supplere dagens behandlingsalternativ for pasienter med lymfekreftformen non-Hodgkin Lymfom (NHL). NHL er en indikasjon med et stort udekket behandlingsbehov og muligheter for såkalt «orphan drugs designation», en incentivordning for få frem nye legemidler til sjeldne sykdommer. NHL representerer er et voksende marked med et antatt markedspotensial på omkring 20 milliarder amerikanske dollar innen 2024. Selskapet har som mål å utvikle Betalutin®, både alene og i kombinasjon med andre behandlingsformer, for behandling av varianter av NHL, og regner med å sende den første regulatoriske søknaden for fremskreden follikulært lymfom i løpet av 2019. Nordic Nanovector planlegger å beholde markedsføringsrettighetene og delta aktivt i kommersialiseringen av Betalutin® i viktige markeder. Selskapet arbeider også med utvikling av en produktportefølje med ARC og andre immunterapier for flere kreftindikasjoner. Ytterligere informasjon om selskapet er tilgjengelig på Denne meldingen er informasjonspliktig etter verdipapirhandelloven §5-12.

Boozt AB’s Interim Report for January – September 2017

Third quarter · Net revenue grew with 45.7% to SEK 454.9 million (312.3) in the quarter · Net revenue grew with 52.8% to SEK 440.6 million (288.3) for in the quarter · Adjusted EBIT amounted to SEK -12.5 million in the quarter (-14.2) · Strong development of cost ratios in the quarter The first nine months  · Net revenue grew with 47.7% to SEK 1,372.2 million (929.1) in the period · Net revenue grew with 54.2% to SEK 1,319.8 million (855.8) for in the period · Adjusted EBIT amounted to SEK -4.1 million in the period (-18.7) · Increased growth outlook: For 2017 net revenue growth is expected to exceed 40% Key highlights · Strong growth in the quarter. Group net revenue was SEK 454.9 million, corresponding to a growth of 45.7% compared to the third quarter last year. We are outgrowing the market significantly. · Positive development of cost ratios in the quarter. Investments made in the fulfilment centre earlier this year have started to pay off.  The Group is growing into scale advantages, and has been able to significantly reduce lead times and cost ratios within the fulfilment process as well as reduce other key cost ratios. · Introducing a step change in the delivery proposition by the end of 2017 – serving 90% of the Nordic region with 100% of the assortment within the same or next day. Launching same day delivery to 3.5 million people during December 2017. Comments by Boozt’s Group CEO Hermann Haraldsson:  We are very pleased that we managed to accelerate the business again during the quarter delivering a growth of 45.7% compared to the third quarter last year. Based on these strong numbers we are raising our outlook for 2017, expecting net revenue growth to exceed 40%. We are especially pleased that the investments in our new fulfilment centre have started to pay off. We crossed “the magic line” in the fulfilment centre during the second half of the quarter, as the fulfilment cost per order (including depreciations and rent), went below last year. This, combined with economies of scale in distribution, resulted in a fulfilment cost ratio (that includes distribution costs) that was lower than the third quarter last year. Due to the increased revenue and the scale advantages associated therewith, our admin & other cost ratio were also lower than last year. All-in-all, the quarter demonstrated that we are seeing the benefits of scale as well as the benefits of the investments we have made in our infrastructure. Status for the first 9 months of this year is that the business looks promising. The Group's net revenue grew with 47.7% to SEK 1,372.2 million during the period, and continued its strong momentum with a growth of 54.2% to SEK 1,319.8 million in the period. We are well positioned in the market. Our curated focus on mainly Nordic brands, offering affordable luxury to the Nordic consumer, is starting to pay off. Telephone conference / audiocast Boozt’s Group CEO, Hermann Haraldsson, and Group CFO, Allan Junge-Jensen, will present the Interim Report at a telephone conference / audiocast at 09.30 CET on Wednesday, November 22, 2017. The presentation will be held in English and will be followed by a Q&A session. Questions can be asked via the telephone conference or in written form via the audiocast.   The presentation material will be available at Boozt’s website .


Summary · Dometic acquires SeaStar Solutions, a leading provider of vessel control systems and aftermarket products to the attractive leisure marine industry · The acquisition strengthens and expands Dometic's position as a global supplier to the marine industry through new product areas, and a broader distribution network and market presence · Cash purchase price of USD 875 million. Fully financed via cash and committed bank facilities · Sales and cost synergies of USD 20 million per annum, fully realized within 3 years · Immediately accretive to Dometic’s operating margin and EPS · Closing expected in Q4 2017, subject to customary conditions and regulatory approval Description of SeaStar Solutions SeaStar Solutions is a leading, global provider of vessel control, fuel systems and system integration to the marine industry. SeaStar Solutions is the market leader in its key product areas with strong market shares. The company today operates some of the strongest brands in the market, such as SeaStar, Xtreme, MOELLER, Optimus and Sierra. The Sierra aftermarket platform is the world’s largest independent marine aftermarket supplier. The company is expected to report sales of USD 320 million and EBITDA of USD 85 million in 2017[1]. OEM accounts for approximately 52% of revenue, whilst aftermarket sales account for approximately 48% of revenue. Capex as a per cent of sales is forecasted to be around 2% for 2017[2] and is expected to remain on this level going forward. SeaStar Solutions is based in North America, operates 8 facilities and employs approximately 1,250 people. Background and reasons for the transaction With the acquisition of SeaStar Solutions, Dometic significantly broadens the marine offering in North America and creates a strong, global platform for further expansion in an industry with good potential for profitable growth. The US outboard boat market in which SeaStar Solutions primarily operates has seen an average growth rate of 8 per cent annually 2010-2016[3]. The combination of Dometic's existing strong position in marine air conditioners, refrigeration and sanitation, with SeaStar Solutions's leadership in vessel control, fuel systems and system integration, will enable the enlarged Dometic to develop and provide an unrivalled offering to the market and fully utilize the broad network of distributors and strong relationships with manufacturers. Expanding in the marine industry has been a strategic priority for Dometic, as it offers attractive market dynamics, strong earnings potential and good opportunities for further expansion. SeaStar Solutions fulfils all prerequisites that Dometic has set for acquired expansion, with proven profitable growth, leading market positions and strong management. The acquisition of SeaStar Solutions is also a strategically important step in Dometic’s ambition to increase its presence in new attractive areas to complement the strong Recreational Vehicle business. "I warmly welcome SeaStar Solutions to Dometic. The acquisition is an excellent strategic fit and greatly reinforces our position in the marine business. The company has market leading positions in several attractive product segments and is a strategic corner stone in our ambition to build a broader global leadership. I welcome SeaStar Solutions and its employees to Dometic”, says Roger Johansson, President and CEO of Dometic. "We are very pleased that Dometic has selected SeaStar Solutions to play a key role in their Marine expansion strategy. Dometic's long-term vision and commitment to be the product leader and number one in the market is very much in line with our existing goals and company culture. The combined businesses will allow us to operate from a very strong platform for further successful expansion and profitable growth”, says Yvan Cote, President, and CEO of SeaStar Solutions. The transaction in brief Completion of the transaction is subject to customary conditions and regulatory approvals. Closing is expected during the fourth quarter 2017. Under the terms of the agreement, Dometic will pay a cash purchase price of USD 875 million for SeaStar Solutions on a cash and debt free basis. Return on investment is estimated to be above cost of capital within 3 years. The transaction is immediately accretive to Dometic’s operating margin and EPS, and is expected to generate sales and cost synergies, including strengthened combined sales platform, supply chain and distribution. Total synergies are estimated to amount to USD 20 million per annum and are expected to be fully realized within 3 years. The cost for cash integration, transaction and refinancing will be charged in the fourth quarter and announced in the year-end report. Transaction financing Commitments have been secured to finance the acquisition of SeaStar Solutions. Net debt / EBITDA ratio at closing of 3.3x. Dometic and SeaStar Solutions will generate strong cash flow and the net debt / EBITDA ratio is expected to be within the target level of 2x in 24 months. Dometic intends to maintain its dividend policy of at least 40 per cent of net profit. Webcast Analysts, investors and media are invited to participate in a telephone conference at 10.00 (CET) November 22 2017, during which President and CEO, Roger Johansson and CFO, Per-Arne Blomquist, will present and answer questions. To participate in the webcast/telephone conference, please dial in five minutes prior to the start of the conference call: SE: +46 8 566 426 69UK: +44 20 3008 9807US: +1 855 831 5948 Link to webcast:  For further information, please contact:  Johan Lundin, Head of Investor Relations & CommunicationsPhone: +46 8 501 025 46Email:  This information is information that Dometic Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on November 22, 2017  Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts or circumstances. The words “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions, identify certain of these forward-looking statements. The forward-looking statements in this announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although Dometic believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors, which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. ABOUT DOMETICDometic is a global market leader in branded solutions for mobile living in the areas of Climate, Hygiene & Sanitation and Food & Beverage. Dometic operates in the Americas, EMEA and Asia Pacific, providing products for use in recreational vehicles, trucks and premium cars, pleasure and workboats, and for a variety of other uses. Dometic offer products and solutions that enrich people’s experiences away from home, whether in a motorhome, caravan, boat or a truck. Our motivation is to create smart and reliable products with outstanding design. We operate 22 manufacturing/assembly sites in nine countries, sell our products in approximately 100 countries and manufacture approximately 85% of products sold in-house. We have a global distribution and dealer network in place to serve the aftermarket. Dometic employs approximately 6,500 people worldwide, had net sales of SEK 12.4 billion in 2016 and is headquartered in Solna, Sweden. ---------------------------------------------------------------------- [1] Pro forma for acquisitions and items affecting comparability [2] Pro forma for acquisitions and items affecting comparability [3] **Source: The National Marine Manufacturers Association

Mercedes-Benz is using two Dreamoc XL3 mixed reality displays for their new pop-up store in Stockholm

“We are truly excited that Mercedes-Benz is using our unique glasses-free mixed reality displays, as a part of their pop-up store. I think the shop is a great example of a successful balance between showcasing the actual products and then creating an inviting and stylish interior with relevant technology that adds meaningful experiences”, says Realfiction CEO Clas Dyrholm. The pop-up store in central Stockholm is created as a temporary showroom at the address Regeringsgatan 65 where customers can experience selected Mercedes-Benz premium cars in two Dreamoc XL3 displays. Realfiction sees car manufacturers as an important customer segment during its ongoing global expansion, as mixed reality experiences are well suited for visualizing one or several car models and their unique features in a limited physical area. The Mercedes-Benz event in Stockholm is a great example of this. Realfictions new product line DeepFrame, a window-like display that allows digital objects to interact over large floor spaces, will make it possible to take this concept to an even higher level going forward. For more information about Realfiction, please contact:  Clas Dyrholm, Founder and CEO  Telephone: +45 25 22 32 81  E-mail:    Certified Adviser   Sedermera Fondkommission is the company’s Certified Adviser.   This information is information that Realfiction Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 22th, 2017. About Realfiction Holding AB Founded in Denmark in 2008, Realfiction is a leading mixed-reality solutions company, a market estimated to reach USD 80 billion by 2025. The company’s first product, Dreamoc, has been sold in over 10.000 units. DeepFrame, a new patent-pending product platform available as mixed-reality displays in larger and smaller formats, was made available to customers in September 2017. DeepFrame enables a wide range of new application areas for companies within entertainment, manufacturing and retail. The platform is also being developed for innovative consumer products. For easy access to Realfiction’s products, the company provides complete solutions that can be purchased, rented or leased in collaboration with a global network of distributors and content creators. Realfiction Holding AB’s share is publicly traded on Nasdaq Stockholm First North under the symbol “REALFI”.  The share’s ISIN code is SE0009920994.

Management changes at Handelsbanken

Göran Stille has been appointed Senior Advisor, with particular responsibility for international regional bank boards and subsidiary boards. He is currently Head of Regional Bank South East Sweden, and will remain part of the Bank’s Senior Management, of which he has been a member since 2008. He takes up his new appointment on 29 December 2017.Anders Fagerdahl has been appointed the new Head of Regional Bank South East Sweden. In this position, he will also be a member of the the Bank’s Senior Management. He is currently Head of the Bank’s operations in Singapore, and will take up his new position on 29 December 2017. Ulrica Stolt Kirkegaard has been appointed at Group level to be responsible for preparing and managing Handelsbanken’s activities relating to Brexit. Since 2014 she has been Chief Executive of Stadshypotek AB, and her new position means that she will leaving the Bank’s Senior Management. Maria Lidström Andersson will succeed Ulrica Stolt Kirkegaard as Chief Executive of Stadshypotek AB on 15 February 2018. In this position, she will become a member of the Bank’s Senior Management. Maria Lidström Andersson is currently Chief Executive of Handelsbanken Finans. A new Chief Executive of Handelsbanken Finans will be recruited in due course.Katarina Grönwall has been appointed Chief Communications Officer. She is currently Senior Vice President, Communications within the Skanska Group. In her new position, Katarina Grönwall will become a member of Handelsbanken’s Senior Management. She will be taking up her new position no later than in May 2018.For further information, please contact: Anders Bouvin, President and Group Chief Executive, +46 8–22 92 20Stefan Nilsson, Acting Chief Communications Officer, +46 8–701 89 04, +46 70–225 91 04Johan Wallqvist, Head of Group Media Relations, +46 8–701 80 47, +46 72–206 34 50 Rolf Marquardt, Chief Financial Officer +46 8 -22 92 20 This information is of the type that Handelsbanken is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication through the agency of the contact person set out above, at 8.15 CET on 22 November 2017. For more information about Handelsbanken, see: 

IK Investment Partners to support Studienkreis

Since its inception in 1974, Studienkreis has developed into one of the leading providers of tutoring services on the German market. The Company operates a dense network of over 1,000 learning centres, offering small group tutoring to c. 60,000 primary and secondary school students across Germany, covering all common subjects as well as special preparatory courses for pre graduation exams. The Company has further developed a true online offering, comprising the Studienkreis App supporting students with their homework and tutoring schedule. Renowned for its high quality tutoring services as well as proven learning concept – developed and refined over 40 years, Studienkreis benefits from high brand awareness and customer satisfaction in the German market and has continuously been certified by various testing institutes. “Customer satisfaction is truly at the centre of our business strategy. Our qualified and certified tutors assess every student individually; personalised support plans, as well as the documented progress are discussed with parents on a regular basis. It is this proven learning concept Studienkreis has built its reputation on. We now embark on the next phase of our growth trajectory with the support from IK and I’m truly excited for the opportunity to even better service our students,” said Lorenz Haase, CEO of Studienkreis. “Studienkreis has a distinctive successful concept and a proven track record. Together with the highly experienced management team, we are looking forward to supporting the Company’s future success as they continue to grow their network and their tutoring offering,” said Anders Petersson, Partner at IK Investment Partners and advisor to the IK Small Cap I Fund. Completion of the transaction is subject to merger control approvals.

Autoliv confirms conclusion of specific part of ongoing investigation with the European Commission

The Company initially communicated in its third quarter earnings release for 2017 that part of the investigation was likely to be concluded shortly. The recorded amount (equivalent to approximately $9.5 million) relates to a discrete portion of the EC investigation relating to two specific car manufacturers, while the more significant portion of its investigation continues. Management does not believe the outcome of this discrete portion of the EC’s investigation provides an indication of the total probable loss associated with the continuing portion of the EC’s investigation, which the Company believes will probably materially affect operating results for the periods in which it becomes estimable. Autoliv cannot currently estimate when a conclusion of the remaining, more significant, part of the investigation is likely to occur. As previously disclosed, Autoliv has, since July 2011, been the subject of an investigation of anti-competitive behavior among suppliers of occupant safety systems in the EU. For further information see Note 16 to the financial statements in Autoliv’s 2016 Annual Report and Note 13 to the financial statements in Autoliv’s 10-Q for the period ended September 30, 2017. Inquiries: MediaThomas Jönsson, Group Vice President, Corporate Communications   Tel +46 (0)8 5872 0627 InvestorsRay Pekar, Vice President Investor Relations Americas   Tel +1 248 794 4537Anders Trapp, Vice President Investor Relations   Tel +46 (0)8 5872 0671 About Autoliv Autoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 80 facilities with 70,000 employees in 27 countries. In addition, the Company has 22 technical centers in ten countries around the world, with 19 test tracks, more than any other automotive safety supplier. Sales in 2016 amounted to about US $10.1 billion. The Company's shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIV sdb). For more information about Autoliv, please visit our company website at Safe Harbor StatementThis release contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements, including without limitation, statements related to the Company’s strategic review of its operating structure or the terms, timing or structure of any such transaction as a result of such review, if any; the outlook for Passive Safety and Electronics as separate businesses; statements related to the future performance of the Company or of any such businesses if any such transaction is completed; other targets regarding the Company’s performance as a single entity; management’s examination of historical operating trends and data, as well as estimates of future sales, operating margin, cash flow, effective tax rate or other future operating performance or financial results, are based upon our current expectations, various assumptions and/or data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “estimates”, “expects”, “anticipates”, “projects”, “plans”, “intends”, “believes”, “may”, “likely”, “might”, “would”, “should”, “could”, or the negative of these terms and other comparable terminology, although not all forward-looking statements contain such words. Because these forward-looking statements involve risks and uncertainties, the outcome could differ materially from those set out in the forward-looking statements for a variety of reasons, including without limitation, changes in light vehicle production; fluctuation in vehicle production schedules for which the Company is a supplier, changes in general industry and market conditions or regional growth or decline; changes in and the successful execution of our capacity alignment, restructuring and cost reduction initiatives and the market reaction thereto; loss of business from increased competition; higher raw material, fuel and energy costs; changes in consumer and customer preferences for end products; customer losses; changes in regulatory conditions; customer bankruptcies, consolidations, or restructurings; divestiture of customer brands; unfavorable fluctuations in currencies or interest rates among the various jurisdictions in which we operate; component shortages; market acceptance of our new products; costs or difficulties related to the integration of any new or acquired businesses and technologies; continued uncertainty in pricing negotiations with customers; successful integration of acquisitions and operations of joint ventures; successful implementation of strategic partnerships and collaborations; our ability to be awarded new business; product liability, warranty and recall claims and investigations and other litigation and customer reactions thereto; (including the resolution of the Toyota recall); higher expenses for our pension and other postretirement benefits, including higher funding requirements for our pension plans; work stoppages or other labor issues; possible adverse results of pending or future litigation or infringement claims; our ability to protect our intellectual property rights; negative impacts of antitrust investigations or other governmental investigations and associated litigation relating to the conduct of our business; tax assessments by governmental authorities and changes in our effective tax rate; dependence on key personnel; legislative or regulatory changes impacting or limiting our business; political conditions; dependence on and relationships with customers and suppliers; the uncertainty as to which strategic alternatives may be available with respect to the Electronics business, whether any transaction will be commenced or completed as a result of such review, and the timing and value of any such transaction; risks related to the potential separation of the Electronics business; and other risks and uncertainties identified under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Reports and Quarterly Reports on Forms 10-K and 10-Q and any amendments thereto. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any forward-looking statements in light of new information or future events, except as required by law.

Stora Enso to divest the Baienfurt sheeting centre

Stora Enso has signed an agreement to divest its sheeting centre business in Baienfurt, Germany to Pyroll, a Finnish converting firm. The sheeting centre operations started in April 2009 and is 100% owned by Stora Enso. This divestment supports Stora Enso’s growth strategy for its consumer board business, where the focus is to generate value to customers by being the global benchmark in high quality virgin fibre carton board. Running sheeting centre operations is not part of Stora Enso’s core business. The new owner has sheeting operations as its core and is in a better position to further develop Baienfurt. Stora Enso will remain a key customer to the Baienfurt sheeting centre. The transaction is expected to be completed during the first quarter of 2018 and it is not expected to have any significant effect on the net debt or financials of Stora Enso. The sheeting centre employs approximately 60 people excluding outsourced personnel and had sales of EUR 15 million in 2016. About the buyerPyroll is one of the leading paper, cardboard, paperboard, and plastic converters in the Nordic countries. Today Pyroll employs nearly 600 people, and turnover is about 100 million euros. Operations are divided into three business branches: Pyroll Packages, Pyroll Paper Merchant, and Pyroll Converting. For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228 Investor enquiries:Ulla Paajanen-Sainio, SVP, Investor Relations, tel. +358 40 763 8767 Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper on global markets. Our aim is to replace fossil-based materials by innovating and developing new products and services based on wood and other renewable materials. We employ some 25 000 people in more than 35 countries, and our sales in 2016 were EUR 9.8 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY).   STORA ENSO OYJ 

Starbreeze, OVERKILL and 505 Games are planning the perfect heist with the ‘Master Plan’ update for PAYDAY 2™: Crimewave Edition

Expansive DLC for PAYDAY 2 available later today on Xbox One, PlayStation™ 4 to follow November 24 in EU and November 28 in US. Starbreeze, OVERKILL – A Starbreeze Studio and 505 Games are planning the perfect crime together by offering the PAYDAY 2: Crimewave Edition  community a fully packed content update –’The Master Plan‘ bundle, available digitally later today on Xbox One with PlayStation 4 release following in the coming days - November 24th in the EU, November 28th for the US. Adding to PAYDAY 2’s already adrenaline-fueled co-op multiplayer shooter experience, The Master Plan will bring an additional 6 premium DLC offering hours of some of the most iconic heisting there has ever been. Watch the Master Plan trailer here: PAYDAY 2: Crimewave Edition brings the tense thrill of planning and pulling off heists as up to four players must work together to complete a number of illegal, strategic and action-heavy jobs, including robbing banks for their big pay day. As missions are completed, players can change up their playstyle with upgrades to their skillset, guns and gear – all in stunning 1080p HD visuals. Available now on Xbox One and soon on PlayStation 4, the latest DLC release for PAYDAY 2: Crimewave Edition, The Master Plan will offer players a cool selection of six premium DLC packs that can be bought in part for $4.99-$6.99 per pack, or purchased together in a bundle for the recommended price of $19.99 – a 40% savings.  The Master Plan packs include: · The John Wick Weapons Pack – $4.99 · Gage Spec Ops Pack – $4.99 · The Scarface™ Heist – $6.99 · The Scarface™ Character Pack – $4.99 · John Wick Heists – $6.99 · Gage Russian Weapon Pack – $4.99 For aspiring heisters looking to start their own crew, PAYDAY 2: Crimewave Edition can be found on the PlayStation Network  and Xbox Live  for $19.99. With the Master Plan release, there will also be a free update that will be pushed to all new and existing PAYDAY 2: Crimewave Edition console users with many free content updates. This free update will include items like the Sangres Character, the Panic Room heist, Heat Street heist, Green Bridge heist, and more. With more than 5.4 million community members on the main PC digital distribution platform Steam, PAYDAY 2 have had more than 160 paid and free updates since its release in 2013. First launched in 2011, PAYDAY is a cooperative first-person shooter computer and video game franchise with more than 16 million units sold on PC, SteamOS, PlayStation 3, Xbox 360, PlayStation 4 and Xbox One. ### Download the latest press assets for PAYDAY 2 here:

Scout Gaming signs deal with Betsson Group

The agreement gives Betsson Group full access to Scout Gaming's DFS platform enabling them to offer a complete Daily Fantasy Sports solution across its subsidiaries and to all its customers. Scout Gaming’s platform is expected to be fully integrated into Betsson's product offering in 2018. "I’m delighted that Betsson Group, one of Europe´s leading online operators, has chosen Scout Gaming as their supplier. The agreement confirms that Daily Fantasy Sports is rapidly gaining ground and is expected to be the next online gaming growth vertical" says, Scout Gaming CEO, Andreas Ternström. "We have evaluated how to extend our sports offering and in particular the possibilities related to Daily Fantasy Sports. Broadening our target audience as well as increasing loyalty among existing players are two key demands we can address with DFS. Scout Gaming not only offers a wide selection of sports but is also able to support local and niche events, which is important to us. Scout also offer the largest European liquidity network, which was an important consideration in our selection process, " commented, Andy Broughton Braithwaite, Betsson Group’s Director of Gaming. For additional information, please contact:Andreas Ternström, CEOTel: +46 706 770 660E-mail: About Scout Gaming GroupScout Gaming Group is a licensed and regulated provider of B2B Daily Fantasy Sports. The company offers a flexible and customizable network based Fantasy Sports solution with support for most sports and leagues through an in-house StatCenter which also provides real-time information to players. Local sports can be provided on request. The Group has well over 50 staff and is headquartered in Stockholm, Sweden with development and operations in Bergen, Norway and Lviv, Ukraine. Sales, support and product management is handled from the office in Malta. About Betsson GroupWith more than 20 brands, including,, and, offering Sportsbook, Casino and Poker, Betsson Group is one of the world’s largest gaming groups, at the heart of entertainment for over five decades. The company’s vision is to provide the best customer experience in the industry – listening to, and learning from, its customers, and then exceeding their expectations – using best-in-class technology and leveraging an abundance of data and insight. Betsson Group is wholly owned by Betsson AB – listed on the Nasday Stockholm Large Cap list.

Cleantech Invest portfolio firm Eagle Filters signs repeat order

Cleantech Invest portfolio company Eagle Filters has received a 300.000€ repeat order from IEC, the largest supplier of electricity in Israel. IEC has been using Eagle’s air filtration products for several years, yielding significant economic and environmental benefits. The order shows, once again, the loyalty of Eagle’s customers. Up to date, none of Eagle’s customers have decided to switch back to traditional filtration after seeing the operational benefits of Eagle’s technology. Eagle Filters enables significant fuel efficiency and therefore CO2 savings for the global energy industry. The company provides high efficiency intake air filtration solutions for gas fired power plants. Utilizing Eagle’s technology in existing gas power plants, energy producers achieve fuel savings in the range of 1-3 MEUR per power plant annually and simultaneously cutting CO2 emissions and urban air pollution. The savings are mainly due to increased fuel efficiency of the turbines because of less fouling of compressor blades when the intake air is efficiently cleaned. Alexander Lidgren, CEO Cleantech Invest comments: “When we measured the impact of our companies, the CO2 savings generated by Eagle are actually the biggest of all our portfolio, which has to do with the scale of these turbines. Every time Eagle lands an order with an electricity provider it has a fairly drastic effect on the amount of natural gas resources needed to produce that electricity.” Eagle’s filtration technology is currently in use in several countries in Asia, Europe, North and South America, and Africa. Among Eagle’s customers is Engie, the world’s largest operator of gas fired power plants, that approved Eagle’s products after a rigorous and lengthy testing process. Eagle’s revenue H1 2017 has doubled from H1 2016. The technology has in the past 2 years been tested by some of the world’s largest gas turbine operators with excellent results and these customers are currently considering deploying the technology at scale. Overall, there are approximately 10 000 gas turbines in the world that could benefit from Eagle’s technology, with an annual savings potential of 7,5 billion EUR. Cleantech Invest owns 28% of Eagle Filters, with options to increase ownership to 40%. Cleantech Invest has communicated, that it will support and accelerate Eagle Filters as one of its core holdings. ”IEC has been an important customer for us and is a world pioneer in utilizing high efficiency filtration. Our close cooperation with IEC in testing our products has been important for our R&D. After verifying the achieved fuel savings for several years, IEC has indicated they will incorporate Eagle’s technology in several other power plants as well”, says Juha Kariluoto CEO of Eagle Filters.

Fazer first in the world to introduce insect bread to grocery stores

Insect food is a significant global phenomenon that is about to land in Finland, too. Since last summer, Fazer has been developing insect bread to be included in the assortment of its in-store bakeries. The ban on selling insects as food was unexpectedly released in Finland on 1 November 2017. Markus Hellström, Managing Director of Fazer Bakery Finland, is thrilled about this: “We wanted to be in the forefront of food revolution. We want to boost growth in the bread category with hand-made artisanal bread, also in the future. In the Fazer in-store bakeries, we can easily bake and test different kinds of novelties. The first-in-the-world Fazer Cricket Bread is a great example of this.”     Innovative bakery develops solutions for the future Fazer Bakery is an innovative actor that constantly revamps its bread category by introducing new kinds of grain and plant based taste sensations to consumers. “According to the “Suuri leipätutkimus*” survey on bread conducted in Finland, good taste, freshness and domestic origin are the main criteria for bread. Finns are known to be willing to try new things, and the Fazer Cricket Bread is an easy way to get a feel of food of the future. Also retail immediately announced they would include it in their assortment,” Markus Hellström goes on to say. Currently, there is not enough cricket flour available for nation-wide sales, so the novelty will be brought to the market in stages. The aim is that Fazer Cricket Bread would be available in all 47 Fazer in-store bakeries in Finland in the next wave. Fazer in-store bakeries bake bread by hand from the very beginning Fazer in-store bakeries have a unique assortment. Dough is made on the spot from flour that comes from Fazer’s own mill, and the dough is left to rest for a long time. The scent of fresh bread tempts more and more Finns, since the number of in-store bakeries is significantly growing. Markus Hellström says: “We can see signs of a ʻbread renaissanceʼ, a new coming of bread. Finnish consumers value hand-made bread. We have 300 professionals in our in-store bakeries who bake bread by hand from the very beginning.” One novelty bread contains 70 house crickets The crickets contained in cricket bread are dried and ground into powder that is added to flour. One Fazer Cricket Bread contains 70 house crickets. Crickets are light; they compose three per cent of the weight of the bread. Juhani Sibakov, Director, Innovation of Fazer Bakery Finland says: “The leading star in our bakery products is always excellent taste. We made a crunchy dough to enhance taste and increase mouthfeel. The result is delicious and nutritious. Cricket bread is a good source of protein. Insects also contain good fatty acids, calcium, iron and vitamin B12.” According to Juhani Sibakov, everything points in the direction that, in the future, insects will be an important ingredient in food also in the western world. “Mankind needs new and sustainable sources of nutrition. According to research, of all the Nordic countries, Finns have the most positive attitudes towards insects**. We are looking forward to seeing how our novelty bread is received”, Juhani Sibakov goes on to say. The Fazer Cricket Bread is one of Fazer Bakery’s future products where flour is replaced with nutritious raw materials. The same philosophy applies to Fazer Root Vegetable Bread and Fazer Seed Bread, where one third of the flour was replaced by vegetables and seeds. The first batch of Fazer Cricket Bread for sale on Friday 24 November Freshly baked Fazer Cricket Bread can be bought in eleven Fazer in-shop bakeries in Finland on Friday 24 November. HOK Prisma shops1                    Prisma Jumbo, Vantaa2                    Prisma Viikki, Helsinki3                    Prisma Kaari Kannelmäki, Hki4                    Prisma Sello, Espoo5                    Prisma Iso Omena, Espoo  Varuboden6                    Prisma Kirkkonummi K shops in the Helsinki area 7                    KCM Myyrmäki, Vantaa8                    KCM Sello, Espoo9                    KCM Iso Omena, Espoo10                  KCM Easton, Helsinki11        KSM Kamppi, Helsinki **Source: Suuri Leipätutkimus 2017, Rednote **Source: Food & Health Nordic report 2017, YouGov® #tulevaisuudenleipä #suomalaistahyvää #sirkkaleipä Additional information: Managing Director Markus Hellström, Fazer Bakery Finland, , tel.: +358 40 732 0057 Director, Innovation Juhani Sibakov, Fazer Bakery Finland,, tel.: +358 40 5363428 Senior Specialist, Communications Taina Lampela-Helin, Fazer Group,, tel.: +358 40 668 4600  Fazer’s media phone line is open on weekdays at 8-16, tel.: +358 40 6682 998 Printable pictures of Fazer Cricket Bread and Fazer in-store ”Media_Press”


Pareto Securities AB has advised RopoHold Oy (“Ropo” or the “Company”), on placing a 3-year EUR 50 million senior secured bond (the “Bonds”). The proceeds from the transaction will be used to refinance existing interest bearing debt, repay shareholder loans, make an extraordinary dividend to the owners of the Company and for general corporate purposes. The Bonds, maturing in December 2020, will bear a floating rate coupon of 3 month Euribor + 7.00 per cent, with interest paid quarterly. The Bonds will be listed on Nasdaq Helsinki within 9 months of the issue date. The transaction was well received by the market, with participation primarily from Swedish and Norwegian institutional investors, coupled with strong demand from other Nordic and continental European accounts. “The bond issue secures the Company’s financing for a foreseeable future and is well suited to support the Owner’s and Management’s growth plans for the Company in its early stages. The flexible financing obtained through the bond will enable the Company to pursue its goal of becoming the leading Finnish provider of invoice lifecycle management, continuing to disrupt the industry as it stands today” says Artti Aurasmaa, CEO of Ropo Capital. Pareto Securities AB acted as Sole Bookrunner in connection with the bond issue. For more information please contact Mats Carlsson, CEO, at +46 8 402 52 86 or Markus Wirenhammar, Head of Debt Capital Markets, +46 70-872 51 86. About Ropo Capital Ropo Capital is a leading Finnish provider of invoice lifecycle management services covering the whole value chain of receivables management. Headquartered in Kuopio, Finland, the Company employs approximately 140 people and serves more than 8,000 customers in Finland spanning from SMEs to large corporates. The Company delivers every 6th invoice in Finland and handles EUR 5 billion in customer assets per year. More information available is at 

Invitation to Webinar: Ericsson Mobility Report

The semi-annual Ericsson (NASDAQ: ERIC) Mobility Report delivers unmatched insights into the present and future of mobile technology usage as well as the proliferation of IoT and connected devices. Please join us for an exclusive one-hour webinar for the launch of our November 2017 edition. Our projections run to 2023 and include: · How the number of subscriptions for technologies such as 5G and LTE will change · How mobile traffic will grow between 2017 and 2023 on applications such as video and social networks · What percentage of the population LTE and 5G will cover in 2023 The report also contains feature articles on: · Why service providers must offer a variety of mobile data options to their customers · How digitalized services enhance live event experiences · What millennial consumers expect from 5G wireless technology Register for the webinar  Content will also be available on demand. NOTES TO EDITORS For media kits, backgrounders and high-resolution photos, please visit FOLLOW US:  MORE INFORMATION AT: News Center 10 719 69 92) 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on

Summary from Gunnebo’s Capital Markets Day 2017

The Capital Markets Day opened with a strategic update from the Group’s President and CEO, Henrik Lange. “Gunnebo has a clear strategy and we are well on the way to implementing it. Both sales regions Asia-Pacific and Americas are performing well. In Region Europe, Middle East and Africa we have a mixed picture where some parts, like Middle East, are performing well whereas others, like France and South Africa, are not.” “We have an agenda in place on how to get back into growth and drive productivity in France. This agenda is focused on growing the topline by developing business in new market segments, increasing productivity through a review of the structure of our French operations, and securing lean procurement and logistics operations. Implementation of the agenda will start during the first half of 2018.” “In South Africa, we have closed the manufacturing unit, allowing full focus on customers and sales.” “Moreover, we have a strong agenda in place to support growth in the main Product Areas, through software and digitisation as well as through targeted non-organic growth.” The day then continued with a financial update from Gunnebo’s CFO, Susanne Larsson, as well as presentations on the three Product Areas, Cash Management, Entrance Security and Safes & Vaults. Finally there was a demonstration of the Gunnebo Retail Solution software platform, which allows all systems and resources in a store to be connected on one open platform, accessible anytime, anywhere. The presentations and a webcast recording from the event will be available on from the evening of November 23. GUNNEBO AB (publ)Group Communications For further information, please contact: Karin Wallström Nordén, SVP Marketing & Communicationstel: +46 10 2095 026,